CN1152886C - Eplerenone crystalline form exhibiting enhanced dissolution rate - Google Patents
Eplerenone crystalline form exhibiting enhanced dissolution rate Download PDFInfo
- Publication number
- CN1152886C CN1152886C CNB008057788A CN00805778A CN1152886C CN 1152886 C CN1152886 C CN 1152886C CN B008057788 A CNB008057788 A CN B008057788A CN 00805778 A CN00805778 A CN 00805778A CN 1152886 C CN1152886 C CN 1152886C
- Authority
- CN
- China
- Prior art keywords
- eplerenone
- compound
- medicine
- crystalline form
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960001208 eplerenone Drugs 0.000 title claims abstract description 689
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 title claims abstract description 634
- 238000004090 dissolution Methods 0.000 title description 27
- 230000001747 exhibiting effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 132
- 238000000034 method Methods 0.000 claims abstract description 88
- 239000003814 drug Substances 0.000 claims abstract description 70
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 238000011282 treatment Methods 0.000 claims abstract description 12
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims abstract description 5
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960002478 aldosterone Drugs 0.000 claims abstract description 5
- 230000001404 mediated effect Effects 0.000 claims abstract description 5
- 238000011321 prophylaxis Methods 0.000 claims abstract 2
- -1 butanone compound Chemical class 0.000 claims description 238
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N Methyl ethyl ketone Natural products CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 181
- 239000002904 solvent Substances 0.000 claims description 180
- 239000002245 particle Substances 0.000 claims description 104
- 239000013078 crystal Substances 0.000 claims description 103
- 238000002425 crystallisation Methods 0.000 claims description 81
- 230000008025 crystallization Effects 0.000 claims description 78
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 77
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 76
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 72
- 239000012453 solvate Substances 0.000 claims description 68
- 238000004807 desolvation Methods 0.000 claims description 64
- 238000007614 solvation Methods 0.000 claims description 57
- 238000009835 boiling Methods 0.000 claims description 52
- 238000002360 preparation method Methods 0.000 claims description 52
- 239000002994 raw material Substances 0.000 claims description 50
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 49
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 42
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 41
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 38
- 239000011877 solvent mixture Substances 0.000 claims description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 28
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 27
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 27
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 23
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 21
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims description 20
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 20
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 20
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 19
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 229940090181 propyl acetate Drugs 0.000 claims description 16
- 229940043232 butyl acetate Drugs 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 125000000457 gamma-lactone group Chemical group 0.000 claims description 10
- 206010019280 Heart failures Diseases 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 8
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 8
- 230000007704 transition Effects 0.000 claims description 8
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 8
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 7
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 claims description 6
- QYAHGDMPUORRQD-UHFFFAOYSA-N 4-oxopentyl acetate Chemical compound CC(=O)CCCOC(C)=O QYAHGDMPUORRQD-UHFFFAOYSA-N 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 6
- 238000002050 diffraction method Methods 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000007952 growth promoter Substances 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 3
- XNLICIUVMPYHGG-UHFFFAOYSA-N methyl n-propyl ketone Natural products CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 claims 3
- 239000007787 solid Substances 0.000 abstract description 67
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 abstract description 11
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 abstract description 11
- 229940044551 receptor antagonist Drugs 0.000 abstract description 11
- 239000002464 receptor antagonist Substances 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 10
- 238000003860 storage Methods 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 63
- 239000012535 impurity Substances 0.000 description 39
- 239000003795 chemical substances by application Substances 0.000 description 37
- 239000000047 product Substances 0.000 description 37
- 238000001816 cooling Methods 0.000 description 36
- 239000000523 sample Substances 0.000 description 34
- 239000003981 vehicle Substances 0.000 description 33
- 239000000463 material Substances 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 28
- 238000000227 grinding Methods 0.000 description 27
- 239000002002 slurry Substances 0.000 description 27
- 238000001757 thermogravimetry curve Methods 0.000 description 26
- 238000001035 drying Methods 0.000 description 25
- 238000002411 thermogravimetry Methods 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 20
- 238000001291 vacuum drying Methods 0.000 description 20
- 238000002329 infrared spectrum Methods 0.000 description 17
- 239000004141 Sodium laurylsulphate Substances 0.000 description 16
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 14
- 239000002775 capsule Substances 0.000 description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 14
- 239000008108 microcrystalline cellulose Substances 0.000 description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 description 14
- 238000012545 processing Methods 0.000 description 14
- 235000010980 cellulose Nutrition 0.000 description 13
- 229920002678 cellulose Polymers 0.000 description 13
- 239000001913 cellulose Substances 0.000 description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 13
- 229920002785 Croscarmellose sodium Polymers 0.000 description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 12
- 229960001681 croscarmellose sodium Drugs 0.000 description 12
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000000080 wetting agent Substances 0.000 description 12
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 238000000354 decomposition reaction Methods 0.000 description 11
- 235000019359 magnesium stearate Nutrition 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
- 239000003966 growth inhibitor Substances 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000314 lubricant Substances 0.000 description 9
- 238000002441 X-ray diffraction Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 229940032147 starch Drugs 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000003828 vacuum filtration Methods 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 125000004185 ester group Chemical group 0.000 description 6
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000000862 absorption spectrum Methods 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 239000008119 colloidal silica Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000012470 diluted sample Substances 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000012452 mother liquor Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 229920000591 gum Polymers 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000004626 scanning electron microscopy Methods 0.000 description 4
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 4
- 229960002256 spironolactone Drugs 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010020571 Hyperaldosteronism Diseases 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 229940083712 aldosterone antagonist Drugs 0.000 description 3
- 239000002170 aldosterone antagonist Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000012296 anti-solvent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 238000010411 cooking Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 102000007451 Steroid Receptors Human genes 0.000 description 2
- 108010085012 Steroid Receptors Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002356 laser light scattering Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000009492 tablet coating Methods 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-N 1-hexadecylpyridin-1-ium;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- KUXGUCNZFCVULO-UHFFFAOYSA-N 2-(4-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=C(OCCO)C=C1 KUXGUCNZFCVULO-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 201000003101 Coloboma Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- PHMHDRYYFAYWEG-UHFFFAOYSA-N Rhapontigenin Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(O)=CC(O)=C1 PHMHDRYYFAYWEG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920003350 Spectratech® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical group C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 239000006061 abrasive grain Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- VEFXTGTZJOWDOF-UHFFFAOYSA-N benzene;hydrate Chemical compound O.C1=CC=CC=C1 VEFXTGTZJOWDOF-UHFFFAOYSA-N 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- PFRWMMTZXJJCTP-UHFFFAOYSA-L calcium hydrogen sulfate hydrate Chemical compound O.S([O-])(O)(=O)=O.[Ca+2].S([O-])(O)(=O)=O PFRWMMTZXJJCTP-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- UBWYRXFZPXBISJ-UHFFFAOYSA-L calcium;2-hydroxypropanoate;trihydrate Chemical compound O.O.O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O UBWYRXFZPXBISJ-UHFFFAOYSA-L 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003933 environmental pollution control Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229950003169 nonoxinol Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940061037 optivar Drugs 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 235000011185 polyoxyethylene (40) stearate Nutrition 0.000 description 1
- 239000001194 polyoxyethylene (40) stearate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035911 sexual health Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical group CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 238000012982 x-ray structure analysis Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- C07J71/0015—Oxiranes at position 9(11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having relatively hich physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.
Description
Invention field
The present invention relates to pharmaceutically active agents, more precisely, the present invention relates to aldosterone receptor antagonist eplerenone (eplerenone) as aldosterone receptor antagonist.Specifically, the present invention relates to the new crystalline form of eplerenone, the method for preparing this crystalline form, the pharmaceutical composition that comprises this crystalline form, use this crystalline form to treat and/or prevent aldosterone-mediated illness and/or disease, comprise for example hypertensive method of illness relevant and disease with aldosteronism, and the application of this crystalline form in the preparation medicine.
Background of invention
Have structure (I) and be called the compound 9 of eplerenone, 11-epoxy-17-hydroxyl-3-oxo is pregnant-4-alkene-7, and 21-dioctyl phthalate hydrogen methyl esters, the gamma lactone reported first is in people's such as Grob US patent 4559332, one class 9 is disclosed in the document, 11-epoxide steroids and salt thereof.Eplerenone is an aldosterone receptor antagonist, and can use the indication for the treatment of aldosterone receptor antagonist with the treatment significant quantity, the treatment illness relevant with aldosteronism for example comprises hypertension, comprises the heart failure and the liver cirrhosis of cardiac insufficiency.
The preparation of drug combination that above-mentioned US patent 4559332 (introducing the present invention with for referencial use) discloses the preparation of eplerenone prevailingly and contained eplerenone.No. 98/25948 international monopoly publication of WO97/21720 and WO discloses preparation and has comprised 9 of eplerenone, other method of 11-epoxide steroids and salt thereof.
People such as Grob (1997), " steroid aldosterone antagonists: improve 9 α, the selectivity of 11-epoxy derivative ",
Helvetica Chimica Acta, 80,566-585 discloses the X-ray structure analysis of the eplerenone solvate that makes by crystallization eplerenone from methylene dichloride/ether solvent system.
People (1989) such as De Gasparo, " aldosterone antagonist: incidence and preventative side effect ",
Journal of Steroid Biochemistry, 32 (13), 223-227 disclose granula be 20 μ m do not prepare the application of eplerenone in the test of single dose eplerenone.
Having the steroid of 20-Luo oxane shown in the active Spironolactone-structure of aldosterone receptor antagonist (II) is commercially available hypertension therapeutic medicine.Yet Spironolactone has the androgen antagonist activity, may cause gynecomastia and impotence in the male sex.It also has weak pregnant preceding activity, may cause menstruation irregular in the women.Therefore, people wish to develop not that for example glucocorticosteroid, progestogen and androgenic steroids receptor system interact and/or other active aldosterone receptor antagonist that broad-spectrum curing scope more is provided eplerenone for example with other steroid receptor system.
People such as Agafonov (1991), " polymorph of Spironolactone ",
Journal of Pharmaceutical Sciences, 80 (2), 181-185 discloses the multiform crystalline form of acetonitrile compound, ethanol compound, ethyl acetate compound, methyl alcohol compound and two kinds of non-solventizations of Spironolactone.Brittan (1999),
Polymorphism in Pharmaceutical Solids, pp.114-116,207,235 and 261 (Marcel Dekker) also disclose these solid-state forms of Spironolactone.
Eplerenone has low-down solubleness in water medium, and the release from oral dosage form in gi tract of this medicine often is the limiting factor that begins to produce curative effect speed after its bioavailability, particularly oral administration.
The invention summary
The invention provides and in water medium, have very fast dissolution rate, and have the new crystalline form of the eplerenone of other peculiar property with respect to other solid-state form of eplerenone.The complete characterization of crystalline form of the present invention is as mentioned below, but for the purpose of convenient, this crystalline form is called " form H ".
Aspect first, the invention provides the new form H of eplerenone itself.Be different from the middle of the feature of another crystalline form that is called " crystalline form L " at form H, form H shows rhombic system, and at 12.0 ± 0.2 ° of 2 θ place the X-ray powder diffraction pattern at peak and fusing point being arranged is about 247 ℃-Yue 251 ℃.
Aspect second, comprise the eplerenone medicine of the eplerenone crystalline form H of detection limit at least but the invention provides.
Aspect the 3rd, the invention provides the eplerenone medicine that is essentially mutually pure eplerenone crystalline form H.Term used herein " mutually pure " is meant the purity with respect to other solid-state form of eplerenone, rather than must refer to have high chemical purity with respect to other compound.
Aspect the 4th, the invention provides the eplerenone crystalline form that when dissolving, can produce the solvation of eplerenone crystalline form H.
Aspect the 5th, the invention provides pharmaceutical composition, wherein comprise eplerenone crystalline form H and one or more pharmaceutically acceptable vehicle, wherein said composition is optional other solid-state form that comprises one or more eplerenone in total eplerenone unitary dose of the about 1000mg of about 10-.
Aspect the 6th, the invention provides the method and the preparation that prepare eplerenone crystalline form H and comprise eplerenone crystalline form H method for compositions.
Aspect the 7th, the invention provides and prevent and/or treat the aldosterone-mediated illness or the method for disease, comprise eplerenone to individual administering therapeutic significant quantity, wherein to have a part at least be eplerenone crystalline form H to the eplerenone of being used.
Others of the present invention are discussed in the application's whole specification sheets.
Summary of drawings
What accompanying drawing 1 was represented is the X-ray powder diffraction pattern of eplerenone crystalline form H.
What accompanying drawing 2 was represented is the X-ray powder diffraction pattern of eplerenone crystalline form L.
What accompanying drawing 3 was represented is the X-ray powder diffraction pattern of the butanone compound of eplerenone.
Accompanying drawing 4 expression be the X-of eplerenone n-propyl alcohol compound the time line powder diagram.
What accompanying drawing 5 was represented is the X-ray powder diffraction pattern of eplerenone tetrahydrofuran (THF) compound.
What accompanying drawing 6 was represented is the X-ray powder diffraction pattern of eplerenone ethyl propionate compound.
What accompanying drawing 7 was represented is the X-ray powder diffraction pattern of eplerenone acetate compound.
What accompanying drawing 8 was represented is the X-ray powder diffraction pattern of eplerenone acetone compound.
What accompanying drawing 9 was represented is the X-ray powder diffraction pattern of eplerenone toluene compound.
What accompanying drawing 10 was represented is the X-ray powder diffraction pattern of eplerenone Virahol compound.
What accompanying drawing 11 was represented is the X-ray powder diffraction pattern of eplerenone ethanol compound.
What accompanying drawing 12 was represented is the X-ray powder diffraction pattern of eplerenone isobutyl acetate compound.
What accompanying drawing 13 was represented is the X-ray powder diffraction pattern of eplerenone n-butyl acetate compound.
What accompanying drawing 14 was represented is the X-ray powder diffraction pattern of eplerenone methyl acetate compound.
What accompanying drawing 15 was represented is dsc (DSC) differential thermogram of the non-grinding eplerenone crystalline form L of direct crystallization from butanone.
Accompanying drawing 16 expression be the DSC differential thermogram of the non-grinding eplerenone crystalline form L that the solvate desolvation by will crystallization high purity eplerenone obtains from butanone makes.
Accompanying drawing 17 expression be to grind the DSC differential thermogram of the eplerenone crystalline form L that makes by desolvation product that will the solvate that crystallization high purity eplerenone obtains from butanone.
What accompanying drawing 18 was represented is the DSC differential thermogram of the non-grinding eplerenone crystalline form L that will make by the solvate desolvation that boiling from appropriate solvent (digestion) low-purity eplerenone obtains.
What accompanying drawing 19 was represented is the DSC differential thermogram of eplerenone n-propyl alcohol compound.
What accompanying drawing 20 was represented is the DSC differential thermogram of eplerenone tetrahydrofuran (THF) compound.
What accompanying drawing 21 was represented is the DSC differential thermogram of eplerenone ethyl propionate compound.
What accompanying drawing 22 was represented is the DSC differential thermogram of eplerenone acetate compound.
What accompanying drawing 23 was represented is the DSC differential thermogram of eplerenone chloroform compound.
What accompanying drawing 24 was represented is the DSC differential thermogram of eplerenone acetone compound.
What accompanying drawing 25 was represented is the DSC differential thermogram of eplerenone toluene compound.
What accompanying drawing 26 was represented is the DSC differential thermogram of eplerenone Virahol compound.
What accompanying drawing 27 was represented is the DSC differential thermogram of eplerenone ethanol compound.
What accompanying drawing 28 was represented is the DSC differential thermogram of eplerenone tert.-butyl acetate compound.
What accompanying drawing 29 was represented is the DSC differential thermogram of eplerenone isobutyl acetate compound.
What accompanying drawing 30 was represented is the DSC differential thermogram of eplerenone n-butyl acetate compound.
What accompanying drawing 31 was represented is the DSC differential thermogram of eplerenone methyl acetate compound.
What accompanying drawing 32 was represented is the DSC differential thermogram of eplerenone propyl acetate compound.
What accompanying drawing 33 was represented is the DSC differential thermogram of eplerenone propyl carbinol compound.
What accompanying drawing 34 was represented is the DSC differential thermogram of eplerenone n-Octanol compound.
What accompanying drawing 35 was represented is infrared (IR) spectrum (DRIFT) of eplerenone crystalline form H.
What accompanying drawing 36 was represented is the IR spectrum (DRIFT) of eplerenone crystalline form L.
What accompanying drawing 37 was represented is the IR spectrum (DRIFT) of the butanone compound of eplerenone.
What accompanying drawing 38 was represented is the IR spectrum (DRIFT) that is present in the eplerenone in the chloroformic solution.
What accompanying drawing 39 was represented is the IR spectrum of eplerenone n-propyl alcohol compound.
What accompanying drawing 40 was represented is the IR spectrum of eplerenone tetrahydrofuran (THF) compound.
What accompanying drawing 41 was represented is the IR spectrum of eplerenone ethyl propionate compound.
What accompanying drawing 42 was represented is the IR spectrum of eplerenone acetone compound.
What accompanying drawing 43 was represented is the IR spectrum of eplerenone toluene compound.
What accompanying drawing 44 was represented is the IR spectrum of eplerenone Virahol compound.
What accompanying drawing 45 was represented is the IR spectrum of eplerenone ethanol compound.
What accompanying drawing 46 was represented is the IR spectrum of eplerenone isobutyl acetate compound.
What accompanying drawing 47 was represented is the IR spectrum of eplerenone n-butyl acetate compound.
What accompanying drawing 48 was represented is the IR spectrum of eplerenone propyl acetate compound.
What accompanying drawing 49 was represented is the IR spectrum of eplerenone methyl acetate compound.
What accompanying drawing 50 was represented is the IR spectrum of eplerenone propylene glycol compound.
What accompanying drawing 51 was represented is the IR spectrum of eplerenone tert.-butyl acetate compound.
What accompanying drawing 52 was represented is the 13C NMR spectrum of eplerenone crystalline form H.
What accompanying drawing 53 was represented is the 13C NMR spectrum of eplerenone crystalline form L.
What accompanying drawing 54 was represented is the thermogravimetry analysis chart of eplerenone butanone compound.
What accompanying drawing 55 was represented is the thermogravimetry analysis chart of eplerenone n-propyl alcohol compound.
What accompanying drawing 56 was represented is the thermogravimetry analysis chart of eplerenone tetrahydrofuran (THF) compound.
What accompanying drawing 57 was represented is the thermogravimetry analysis chart of eplerenone ethyl propionate compound.
What accompanying drawing 58 was represented is the thermogravimetry analysis chart of eplerenone acetate compound.
What accompanying drawing 59 was represented is the thermogravimetry analysis chart of eplerenone chloroform compound.
What accompanying drawing 60 was represented is the thermogravimetry analysis chart of eplerenone acetone compound.
What accompanying drawing 61 was represented is the thermogravimetry analysis chart of eplerenone toluene compound.
What accompanying drawing 62 was represented is the thermogravimetry analysis chart of eplerenone Virahol compound.
What accompanying drawing 63 was represented is the thermogravimetry analysis chart of eplerenone ethanol compound.
What accompanying drawing 64 was represented is the thermogravimetry analysis chart of eplerenone isobutyl acetate compound.
What accompanying drawing 65 was represented is the thermogravimetry analysis chart of eplerenone n-butyl acetate compound.
What accompanying drawing 66 was represented is the thermogravimetry analysis chart of eplerenone methyl acetate compound.
What accompanying drawing 67 was represented is the thermogravimetry analysis chart of eplerenone n-propyl acetate compound.
What accompanying drawing 68 was represented is the thermogravimetry analysis chart of eplerenone propylene glycol compound.
What accompanying drawing 69 was represented is the thermogravimetry analysis chart of eplerenone propyl carbinol compound.
What accompanying drawing 70 was represented is the thermogravimetry analysis chart of eplerenone n-Octanol compound.
What accompanying drawing 71 was represented is the thermogravimetry analysis chart of eplerenone tert.-butyl acetate compound.
Accompanying drawing 72 expression be the scanning electron microscopy of the eplerenone crystalline form L that makes by butanone compound desolvation with eplerenone.
Accompanying drawing 73 expression be the scanning electron microscopy of the eplerenone crystalline form L that makes by direct crystallization from ethyl acetate.
That accompanying drawing 74 is represented is isolating 4 α from butanone, 5 α; 9 α, 11 α-diepoxy-17-hydroxyl-3-oxo-17 alpha-pregnane-7 α, 21-dioctyl phthalate hydrogen 7-methyl esters, the X-ray powder diffraction pattern of gamma lactone (" diepoxide ") crystalline form.
That accompanying drawing 75 is represented is isolating 11 α from Virahol, 12 alpha-epoxy-17s-hydroxyl-3-oxo-17 α-pregnant-4-alkene-7 α, 21-dioctyl phthalate hydrogen 7-methyl esters, the X-ray powder diffraction pattern of gamma lactone (" 11, the 12-epoxide ") crystalline form.
That accompanying drawing 76 is represented is isolating 17-hydroxyl-3-oxo-17 α from propyl carbinol-pregnant-4,9 (11)-diene-7 α, 21-dioctyl phthalate hydrogen 7-methyl esters, the X-ray powder diffraction pattern of gamma lactone (" 9,11-alkene ") crystalline form.
What accompanying drawing 77 was represented is for the relevant polymorphic form of enantiotrophy, the relation between Gibbs free energy and the temperature.
Accompanying drawing 78 expression be to derive to have mixed (a) 0%, (b) 1%, (c) 3% and (d) the X-ray powder diffraction pattern of the wet cake of butanone crystalline butanone compound of 5% diepoxide.
Accompanying drawing 79 expression be to derive to have mixed (a) 0%, (b) 1%, (c) 3% and (d) the X-ray powder diffraction pattern of the butanone crystalline drying solid of 5% diepoxide.
Accompanying drawing 80 expression be the X-ray powder diffraction pattern of the drying solid that obtains from the butanone crystallization of mixing 3% diepoxide, wherein (a) do not grind this solvate before the drying, is to have ground this solvate before the drying (b).
Accompanying drawing 81 expression be derive from mixed (a) 0%, (b) 1%, (c) 5% and (d) 10% 11, the X-ray powder diffraction pattern of the wet cake of the butanone crystalline butanone compound of 12-epoxide.
Accompanying drawing 82 expression be to derive to have mixed (a) 0%, (b) 1%, (c) 5% and (d) 10%11, the X-ray powder diffraction pattern of the butanone crystalline drying solid of 12-epoxide.
This paper embodiment 7 that is based on of accompanying drawing 83 expressions shows the data that 7A reported, the isometric chart of product purity, material purity, speed of cooling and terminal temperature.
What accompanying drawing 84 was represented is in order to determine product purity is had the variable of remarkable statistics influence, to use half standard map of the isometric chart drafting of accompanying drawing 83.
Accompanying drawing 85 is based on the interaction diagram of this paper embodiment 7 table data that 7A reported, its expression be the influence of the interaction partners product purity between material purity and the speed of cooling.
This paper embodiment 7 that is based on of accompanying drawing 86 expressions shows the data that 7A reported, the isometric chart of form H weight fraction, material purity, speed of cooling and terminal temperature.
What accompanying drawing 87 was represented is in order to determine the form H weight fraction is had the variable of remarkable statistics influence, to use half standard map of the isometric chart drafting of accompanying drawing 86.
Accompanying drawing 88 is based on the interaction diagram of this paper embodiment 7 table data that 7A reported, its expression be the influence of the interaction partners form H weight fraction between material purity and the terminal temperature.
What accompanying drawing 89 was represented is the x-ray diffraction pattern of amorphous eplerenone.
What accompanying drawing 90 was represented is the DSC differential thermogram of amorphous eplerenone.
What accompanying drawing 91 was represented is the dissolution rate of 4 eplerenone polymorphic samples.
Detailed Description Of The Invention
The same with composition as all medical compounds, the chemistry of eplerenone and physical property are extremely important aspect its business development. These character include but not limited to: (1) packing character is molal volume, density and hygroscopicity for example, (2) for example fusion temperature, vapour pressure and solubility of macroscopic property, (3) for example dissolution velocity and stability (are included in the stability under the environmental condition to kinetic property, especially to the stability of moisture, with the stability under storage requirement), (4) for example surface area, wettable, interfacial tension and shape of surface nature, (5) engineering properties is hardness, hot strength, compressibility, operability, flowability and Combination for example; (6) filtering property. These character can affect processing and the storage of the pharmaceutical composition that for example comprises eplerenone. The solid-state form that can improve the eplerenone of one or more these character with respect to other solid-state form is desirable.
The invention provides the new solid-state form of eplerenone. Specifically, these solid-state forms comprise crystalline form (being called " form H " and " crystalline form L ") and the amorphous eplerenone of the crystalline form of various solvations, at least two kinds of non-solvents and non-hydrated. With respect to describe in this article and disclosed other solid-state form in the literature, the various solid-state forms of the eplerenone of describing in this application have one or more above-mentioned favourable chemistry and/or physical propertys. In the desired priority document of this paper, form H and crystalline form L are called " crystalline form I " and " Form II ", and sometimes respectively as " high-melting-point polymorph " and " low melting point polymorph ".
The present invention relates to eplerenone crystalline form H. Compare with for example eplerenone crystalline form L, be lower than under the change transition temperature temperature of (as discussed below), form H shows faster dissolution velocity (fast about 30%) in aqueous medium. When the dissolving of eplerenone in intestines and stomach is when eplerenone is discharged into the rate controlling step of target cell or tissue, dissolve faster the bioavilability that improvement generally can be provided. Therefore, form H can provide and compare the bioavilability feature that is improved with crystalline form L. In addition, with respect to the solid-state form with low dissolution velocity, selection have the eplerenone solid-state form of very fast dissolution velocity can be same so that larger elasticity is arranged when the excipient of selecting pharmaceutical composition and compounding pharmaceutical composition, particularly all the more so when planning rapidly the release eplerenone.
With respect to other solid-state form, crystalline form L also has advantage. Particularly, compare with for example eplerenone crystalline form H, be lower than under the change transition temperature temperature of (as discussed below), crystalline form L has stronger physical stability. Do not need special processing or storage requirement and avoided frequently carrying out eplerenone solid-state form that the stock changes for example crystalline form L be desirable. For example, the eplerenone solid-state form that (for example during grinding the material of eplerenone with the surface area that obtains to have the particle diameter that reduces and increase) has physical stability during being chosen in processing, needing can to avoid special processing conditions and usually by this special processing conditions bring expensive. Similarly, be chosen under the wide region storage requirement eplerenone solid-state form that (especially will consider the difference that may occur may storage requirement) has physical stability during the useful life of eplerenone product, can avoid generation in the eplerenone can cause product loss or destroy polymorphic or other degradability that product renders a service changing. Therefore, the eplerenone solid-state form of selecting to have stronger physical stability for example crystalline form L can provide the significant benefit of the eplerenone form that is better than less stable.
The invention still further relates to the eplerenone crystalline form of solvation. The crystalline form of these solvations can be used as the intermediate of preparation form H and crystalline form L eplerenone; In the context of the invention, what make special concern is the eplerenone crystalline form that can produce the solvation of eplerenone crystalline form H when dissolving. The crystalline form of using solvation is can cause crystal " inner micronizing " when the desolvation as the special advantage of intermediate, hereinafter will discuss it in the application. " inner micronizing " like this can reduce the necessity of grinding, perhaps there is no need fully to grind. In addition, when needs grind in addition, grinding some solvates before the desolvation step than after the crystalline form desolvation with solvation, grinding form H or L is easy.
The eplerenone crystalline form of acceptable solvent also can directly be used in the pharmaceutical composition. In one embodiment, being used for directly, the solvation crystalline form of this pharmaceutical composition of preparation does not comprise carrene, isopropyl alcohol or ether; In another embodiment, do not comprise carrene, isopropyl alcohol, ether, butanone or ethanol; In an embodiment again, do not comprise carrene, isopropyl alcohol, ether, butanone, ethanol, ethyl acetate or acetone. Use most preferably for this, the eplerenone crystalline form of solvation is substantially devoid of non-acceptable solvent.
The solvation crystalline form of using in pharmaceutical composition comprises pharmaceutically acceptable higher and/or hydrogen bonding solvent usually and preferably, such as but not limited to butanols. It is believed that the set of solvation crystalline form can provide different dissolution velocities, and when the dissolving of eplerenone in intestines and stomach is when eplerenone is discharged into the rate controlling step of target cell or tissue, with respect to form H and crystalline form L, the solvation crystalline form can provide different bioavilabilities.
The invention still further relates to the amorphous substance of eplerenone. Amorphous eplerenone can be used as the intermediate of preparation form H and crystalline form L. In addition, it is believed that amorphous eplerenone can provide different dissolution velocities, and when amorphous eplerenone be present in the pharmaceutical composition and when the dissolving of eplerenone in intestines and stomach be when eplerenone is discharged into the rate controlling step of target cell or tissue, with respect to form H and crystalline form L, so amorphous eplerenone can provide different bioavilabilities.
Also it is worth noting the combination of the solid-state form of the eplerenone crystalline form that is selected from eplerenone crystalline form H, eplerenone crystalline form L, solvation and amorphous eplerenone. Such combination can be used for for example preparing the pharmaceutical composition with various dissolving characteristics, comprises controlled release composition. In one embodiment of the invention, the combination of solid-state form is provided, but wherein comprise at least eplerenone crystalline form H of detection limit, remainder is to be selected from the eplerenone crystalline form of eplerenone crystalline form L, solvation and one or more solid-state forms of amorphous eplerenone.
Purpose according to the eplerenone solid-state form is used, and can be of value to processing by the combination of selecting specific solid state form or specific solid state form.For example, mutually pure crystalline form L is easier to preparation than mutually pure form H usually.And form H is easier to preparation than mutually pure crystalline form L usually with the mixture of crystalline form L, and makes it possible to use the eplerenone raw material with low chemical purity.With compare by the course of processing that solvation crystalline form intermediate desolvation is carried out, in composition, use the solvation crystalline form to replace form H or crystalline form L can save a step, i.e. desolvation step.Perhaps, direct crystallization goes out crystalline form L in solvation crystalline form intermediate preparation and the desolvated appropriate solvent if for example never relate to, and also can save the desolvation step.Such method has hereinafter been described in more detail.
Definition
In this article, term " amorphous " refers to solid-state when being used for eplerenone, and wherein this eplerenone molecule exists with the lack of alignment form, and does not form tangible lattice or structure cell.When carrying out the X-ray powder diffraction, amorphous eplerenone does not produce any characteristic crystal peak.
When mentioning the boiling point of material or solution in this article, term " boiling point " refers to this material or the boiling point of solution under applicable treatment condition.
In this article, term " crystalline form " is used for eplerenone and refers to solid-state form, and wherein the eplerenone molecular arrangement forms the lattice (i) that significantly contains structure cell and (ii) produce diffraction peak when carrying out x-ray radiation.
But according to the applied environment relevant with the eplerenone feedstock production, term " crystallization " can refer to crystallization and/or recrystallization when being used for the application.
In this article, term " boiling " refers to a kind of method, wherein under applicable treatment condition, the slurries of solid eplerenone in solvent or solvent mixture is heated under the boiling point of solvent or solvent mixture.
Term used herein " direct crystallization " is meant directly crystallization eplerenone from The suitable solvent, and does not form the intermediate flux crystalline solid forms of eplerenone, and desolvation not.
Term used herein " eplerenone medicine " is meant the eplerenone that context limited self as using this term, and can refer to the eplerenone do not prepared or as the eplerenone of pharmaceutical composition component.
Term used herein " particle diameter " is meant that for example the particle diameter of centrifugal mensuration is coiled in laser light scattering, the mobile segmentation in negative area, the related spectroscopy of photon or garden by conventional particle diameter detection technique well known in the art." D
90Particle diameter " refers to such particle diameter, promptly measures by so conventional particle diameter detection technique 90% particle grain size is arranged less than this D
90Particle diameter.
Term " DSC " is meant dsc.
Term " HPLC " is meant high pressure lipuid chromatography (HPLC).
Term " IR " is meant infrared spectroscopy.
In this article, unless other limit, term " purity " is meant the chemical purity of the eplerenone of measuring according to conventional H PLC detection method.In this article, " low-purity eplerenone " refers generally to contain the eplerenone of the form H crystal growth promoters and/or the crystalline form L crystal growth inhibitor of significant quantity.In this article, " high purity eplerenone " refers generally to not contain or contain the eplerenone less than the form H crystal growth promoters and/or the crystalline form L crystal growth inhibitor of significant quantity.
Term " phase purity " is meant about specific crystalline or unbodied eplerenone, as the eplerenone solid solid purity of measuring by the infrared spectrum analysis of describing herein.
Term " XPRD " is meant the X-ray powder diffraction.
Term " rpm " is meant rotations per minute.
Term " TGA " is meant the TGA analysis.
Term " T
m" be meant fusing point.
The feature of crystalline form
1, molecular conformation
The monocrystalline x-ray analysis shows the orientation difference of the molecular conformation difference of eplerenone between form H and crystalline form L, the particularly ester group of cyclopentanoperhydro-phenanthrene 7-position.The orientation of this ester group can be by the definition of C8-C7-C23-O1 torsion(al)angle.
In the lattice of form H, in the conformation that the eplerenone molecule adopts on the 7-position methoxyl group and the c h bond of ester approximately be in line, and carbonyl approximately is positioned at the center of B-cyclopentanoperhydro-phenanthrene.The C8-C7-C23-O1 torsion(al)angle approximately is-73.0 ° in this conformation.In this orientation, the carbonylic oxygen atom of ester group (O1) and 9, the Sauerstoffatom of 11-oxirane ring (O4) is contact closely.The distance of O1-O4 is about 2.97 dusts, and it just is lower than Van der Waals contact distance-3.0 dusts (van der Waals radius of supposing Sauerstoffatom is 1.5 dusts).
In the lattice of crystalline form L, in the conformation that the eplerenone molecule adopts with respect to form H this ester group approximately rotated 150 °, and the C8-C7-C23-O1 torsion(al)angle is+76.9 ° approximately.In this orientation, the methoxyl group of this ester directly with 4 of A-cyclopentanoperhydro-phenanthrene, 5-alkene part is relative.In this orientation, to compare with the distance that form H is determined, (O1, O2) with 9, the distance between the Sauerstoffatom of 11-oxirane ring (O4) has all strengthened each Sauerstoffatom of this ester group.The O2-O4 distance is about 3.04 dusts, just is higher than Van der Waals contact distance.The O1-O4 distance is about 3.45 dusts.
As if in the solvation crystalline form of analyzing by the monocrystalline X-ray diffraction, the eplerenone molecule adopts the conformation of crystalline form L feature.
2.X-ray powder diffraction
Analyze the various crystalline forms of eplerenone with Siemens D5000 powdery diffractometry meter or Inel Multipurpose diffractometer.For Siemens D5000 powdery diffractometry meter, for 2 θ values, measure raw data from 2-50, its spacing is 0.020 and pitch period is 2 seconds.For the InelMultipurpose diffractometer, sample is placed the aluminum sample holder, and collect 30 minutes raw data simultaneously in all 2 θ values.
Table 1A, 1B and 1C have provided the important parameter (x-ray radiation, wavelength are 1.54056 dusts) of main peaks of the butanone compound (making by the conversion of room temperature slurries in butanone high purity eplerenone) of form H (making by the ethanol compound desolvation that boiling low-purity eplerenone is obtained), crystalline form L (making by the butanone compound desolvation that recrystallization high purity eplerenone is obtained) and eplerenone crystalline form respectively according to 2 θ values and intensity.
The less displacement of peak position may appear in the diffractogram of form H and crystalline form L, this be the imperfect institute of the spacing of crystal diffraction face extremely, and this (being the desolvation of solvent compound) that to be the preparation approach of form H and crystalline form L cause.In addition, form H is isolating from the solvate by the preparation of boiling crude product eplerenone.This method causes the overall chemical purity of form H lower (about 90%).At last, estimate that some displacements have appearred in the diffraction peak position of eplerenone solvation form owing to increase in the flowability of the solvent channel internal solvent molecule of lattice.
Table 1A:X-ray diffraction data, form H
| Angle |
| 2 θ | D-spacing | Intensity Cps | Intensity % |
| ?6.994 | 12.628 | 1188 | 7.2 |
| ?8.291 | 10.655 | 2137 | 13.0 |
| ?10.012 | 8.827 | 577 | 3.5 |
| ?11.264 | 7.849 | 1854 | 11.3 |
| ?12.040 | 7.344 | 7707 | 46.8 |
| ?14.115 | 6.269 | 3121 | 19.0 |
| ?14.438 | 6.130 | 15935 | 96.8 |
| ?15.524 | 5.703 | 637 | 3.9 |
| ?16.169 | 5.477 | 1349 | 8.2 |
| ?16.699 | 5.305 | 1663 | 10.1 |
| ?16.940 | 5.230 | 1692 | 10.3 |
| ?17.147 | 5.167 | 2139 | 13.0 |
| ?17.660 | 5.018 | 6883 | 41.8 |
| ?17.910 | 4.949 | 16455 | 100.0 |
| ?18.379 | 4.823 | 3106 | 18.9 |
| ?18.658 | 4.752 | 1216 | 7.4 |
| ?19.799 | 4.480 | 1499 | 9.1 |
| ?20.235 | 4.385 | 383 | 2.3 |
| ?21.707 | 4.091 | 1267 | 7.7 |
| ?21.800 | 4.073 | 1260 | 7.7 |
| ?21.959 | 4.044 | 1279 | 7.8 |
| ?22.461 | 3.955 | 4264 | 25.9 |
| ?23.191 | 3.832 | 1026 | 6.2 |
| ?23.879 | 3.723 | 1000 | 6.1 |
| | D-spacing | Intensity Cps | Intensity % |
| 24.599 | 3.616 | 1688 | 10.3 |
| 25.837 | 3.445 | 931 | 5.7 |
| 26.034 | 3.420 | 686 | 4.2 |
| 26.868 | 3.316 | 912 | 5.5 |
| 27.093 | 3.288 | 1322 | 8.0 |
| 27.782 | 3.209 | 1236 | 7.5 |
| 28.340 | 3.147 | 1845 | 11.2 |
| 28.861 | 3.091 | 957 | 5.8 |
| 29.866 | 2.9892 | 745 | 4.5 |
| 30.627 | 2.9166 | 992 | 6.0 |
| 31.108 | 2.8726 | 1205 | 7.3 |
| 33.215 | 2.6951 | 1287 | 7.8 |
| 33.718 | 2.6560 | 802 | 4.9 |
| 34.434 | 2.6024 | 914 | 5.6 |
Table 1B:X-ray diffraction data, crystalline form L
| Angle |
| 2 θ | D-spacing | Intensity Cps | Intensity % |
| 7.992 | 11.054 | 11596 | 26.6 |
| 10.044 | 8.799 | 12048 | 27.6 |
| 11.206 | 7.889 | 4929 | 11.3 |
| 12.441 | 7.109 | 1747 | 4.0 |
| 12.752 | 6.936 | 4340 | 9.9 |
| 13.257 | 6.673 | 2444 | 5.6 |
| 14.705 | 6.019 | 43646 | 100 |
| 15.460 | 5.727 | 2670 | 6.1 |
| 15.727 | 5.630 | 7982 | 18.3 |
| 16.016 | 5.529 | 3519 | 8.1 |
| 17.671 | 5.015 | 8897 | 20.4 |
| 17.900 | 4.951 | 2873 | 6.6 |
| 18.352 | 4.830 | 612 | 1.4 |
| 18.703 | 4.740 | 689 | 1.6 |
| 19.524 | 4.543 | 1126 | 2.6 |
| 20.103 | 4.413 | 3753 | 8.6 |
| 20.630 | 4.302 | 1451 | 3.3 |
| 21.067 | 4.214 | 876 | 2.0 |
| 21.675 | 4.097 | 2760 | 6.3 |
| 22.232 | 3.995 | 1951 | 4.5 |
| 22.652 | 3.922 | 1657 | 3.8 |
| 23.624 | 3.763 | 827 | 1.9 |
| 24.279 | 3.663 | 1242 | 2.8 |
| 25.021 | 3.556 | 5144 | 11.8 |
| 25.485 | 3.492 | 1702 | 3.9 |
| 25.707 | 3.463 | 2493 | 5.7 |
| | D-spacing | Intensity Cps | Intensity % |
| 26.251 | 3.392 | 1371 | 3.1 |
| 26.850 | 3.318 | 1970 | 4.5 |
| 27.319 | 3.262 | 1029 | 2.4 |
| 27.931 | 3.192 | 440 | 1.0 |
| 27.969 | 3.187 | 440 | 1.0 |
| 28.937 | 3.083 | 1128 | 2.6 |
| 29.703 | 3.005 | 1211 | 2.8 |
| 30.173 | 2.9594 | 1506 | 3.5 |
| 30.584 | 2.9206 | 1602 | 3.7 |
| 30.885 | 2.8928 | 1550 | 3.6 |
| 31.217 | 2.8628 | 1068 | 2.4 |
| 31.605 | 2.8285 | 1038 | 2.4 |
| 32.059 | 2.7895 | 1211 | 2.8 |
| 32.640 | 2.7412 | 684 | 1.6 |
| 32.747 | 2.7324 | 758 | 1.7 |
| 33.460 | 2.6759 | 506 | 1.2 |
| 34.194 | 2.6201 | 1085 | 2.5 |
| 34.545 | 2.5943 | 915 | 2.1 |
Table 1C:X-ray diffraction data, the butanone compound
| Angle |
| 2 θ | D-spacing | Intensity Cps | Intensity % |
| 7.584 | 11.648 | 5629 | 32.6 |
| 7.753 | 11.393 | 15929 | 92.3 |
| 10.151 | 8.707 | 2877 | 16.7 |
| 11.310 | 7.817 | 701 | 4.1 |
| 12.646 | 6.994 | 1027 | 5.9 |
| 13.193 | 6.705 | 15188 | 88.0 |
| 13.556 | 6.526 | 14225 | 82.4 |
| 14.074 | 6.287 | 1966 | 11.4 |
| 14.746 | 6.002 | 2759 | 16.0 |
| 15.165 | 5.837 | 801 | 4.6 |
| 15.548 | 5.694 | 1896 | 11.0 |
| 17.031 | 5.202 | 7980 | 46.2 |
| 17.280 | 5.127 | 17267 | 100.0 |
| 17.706 | 5.005 | 6873 | 39.8 |
| 18.555 | 4.778 | 545 | 3.2 |
| 18.871 | 4.699 | 1112 | 6.4 |
| 19.766 | 4.488 | 1704 | 9.9 |
| 20.158 | 4.401 | 1396 | 8.1 |
| 20.725 | 4.282 | 2644 | 15.3 |
| 21.787 | 4.076 | 1127 | 6.5 |
| 22.060 | 4.026 | 451 | 2.6 |
| 22.864 | 3.886 | 1542 | 8.9 |
| | D-spacing | Intensity Cps | Intensity % |
| ?23.412 | 3.796 | 14185 | 82.2 |
| ?23.750 | 3.743 | 1154 | 6.7 |
| ?24.288 | 3.662 | 3063 | 17.7 |
| ?25.253 | 3.524 | 1318 | 7.6 |
| ?25.503 | 3.490 | 1736 | 10.1 |
| ?25.761 | 3.455 | 1225 | 7.1 |
| ?26.176 | 3.402 | 1346 | 7.8 |
| ?26.548 | 3.355 | 1098 | 6.4 |
| ?27.357 | 3.257 | 1944 | 11.3 |
| ?27.605 | 3.229 | 2116 | 12.3 |
| ?27.900 | 3.195 | 858 | 5.0 |
| ?28.378 | 3.142 | 583 | 3.4 |
| ?28.749 | 3.103 | 763 | 4.4 |
| ?29.300 | 3.046 | 1182 | 6.8 |
| ?29.679 | 3.008 | 2606 | 15.1 |
| ?30.402 | 2.9377 | 2184 | 12.6 |
| ?30.739 | 2.9063 | 648 | 3.8 |
The instance graph of the x-ray diffraction pattern of the butanone compound crystalline form of form H, crystalline form L and eplerenone is seen Fig. 1 respectively, 2 and 3.Form H has demonstrated the difference peak at 7.0 ± 0.2,8.3 ± 0.2 and 12.0 ± 0.2 ° of 2 θ.Crystalline form L has demonstrated the difference peak at 8.0 ± 0.2,12.8 ± 0.2 and 13.3 ± 0.2 ° of 2 θ.The crystalline form of butanone solventization has demonstrated the difference peak at 7.6 ± 0.2,7.8 ± 0.2 and 13.6 ± 0.2 ° of 2 θ.
Accompanying drawing 4-14 has shown the instance graph of the x-ray diffraction pattern of following eplerenone solvate crystalline form respectively: n-propyl alcohol compound, tetrahydrofuran (THF) compound, ethyl propionate compound, acetate compound, acetone compound, toluene compound, Virahol compound, ethanol compound, isobutyl acetate compound, n-butyl acetate compound and methyl acetate compound.
3. fusing/decomposition temperature
Measure the fusing and/or the decomposition temperature of the eplerenone crystalline form of non-solventization with TA Instruments 2920 differential scanning calorimeters.Each sample (1-2mg) placed sealing or unsealed aluminum pot and with the heating of about 10 ℃/minute heat-up rate.Fusing/decomposition range from fusing/decomposition endotherm extrapolation begin define to maximum value.
The fusing of eplerenone crystalline form H and crystalline form L is with the loss of the solvent of catching in decomposition and the lattice.The influence of solids treatment before fusing/decomposition temperature is also analyzed.For example, by direct crystallization from appropriate solvent or will be in the mixture of appropriate solvent or solvent the non-grinding crystalline form L (D that makes of the solvate desolvation that obtains of crystallization high purity eplerenone
90Particle diameter is about 180-450 μ m) general fusing/decomposition range be about 237 ℃-Yue 242 ℃.Crystalline form L (the D that grinds
90Particle diameter is about the about 100 μ m of 80-) (by recrystallisation solvent compound from the solution of high purity eplerenone appropriate solvent or solvent mixture, with this solvate desolvation, and grinding resulting crystalline forms L makes) generally have the fusing/decomposition temperature scope of low and broad, be about 223 ℃-Yue 234 ℃.Form H (the D of the non-grinding that makes by the solvate desolvation that boiling low-purity eplerenone is obtained
90Particle diameter is about 180-450 μ m) generally have higher fusing/decomposition range, be about 247 ℃-Yue 251 ℃.(a) the crystalline form L of the non-grinding that directly crystallization prepares from butanone, (b) by will be from butanone the crystalline form L of the non-grinding for preparing of the solvate desolvation that obtains of crystallization high purity eplerenone, (c) the crystalline form L for preparing by the desolvated solvate that grinds crystallization high purity eplerenone acquisition from butanone, (d) by will be from butanone the example of DSC differential thermogram of form H of non-grinding of the solvate desolvation preparation that obtains of boiling low-purity eplerenone, respectively as accompanying drawing 15, shown in 16,17 and 18.
Measure the DSC differential thermogram of the solvation form of eplerenone with Perkin Elmer Pyris 1 differential scanning calorimeter.Each sample (1-2mg) placed unsealed aluminum pot and with the heating of 10 ℃/minute heat-up rate.When from the solvate lattice solvent loss being arranged, one or more endothermic processes at a lower temperature are with the variation of enthalpy.Top temperature endotherm (one or more) is relevant with the fusing/decomposition of eplerenone crystalline form L or form H.Accompanying drawing 19-34 has shown the example of DSC differential thermogram of the solvation crystalline form of following eplerenone: be respectively n-propyl alcohol compound, tetrahydrofuran (THF) compound, ethyl propionate compound, acetate compound, chloroform compound, acetone compound, toluene compound, Virahol compound, ethanol compound, tert.-butyl acetate compound, isobutyl acetate compound, butylacetate compound, methyl acetate compound, propyl acetate compound, propyl carbinol compound and n-Octanol compound.
4. infrared absorption spectrum
With Nicolet DRIFT (diffuse reflectance infrared fourier transformation) Magna is the infrared absorption spectrum that 550 spectrographs obtain non-solvent eplerenone crystalline form H and crystalline form L.Use Spectra-Tech collector system and little sample cup.Analytic sample in Potassium Bromide (5%) and from 400 to 4000cm
-1Scanning.With the infrared absorption spectrum of Bio-rad FTS-45 spectrograph acquisition in rare chloroformic solution (3%) or the eplerenone in the solvation crystalline form.Solution pool with 0.2mm path length band sodium chloride salt plate is analyzed the chloroformic solution sample.With IBM little-MIR (multi-functional internal reflection degree) utility appliance collects solvate FTIR spectrum.From 400 to 4000cm
-1Scanning samples.(a) form H, (b) crystalline form L, (c) butanone compound and (d) example of the infrared absorption spectrum of the eplerenone in chloroformic solution respectively as accompanying drawing 35,36, shown in 37 and 38.
Table 2 discloses the exemplary absorbent band of the eplerenone of form H, crystalline form L and butanone compound crystalline form.The exemplary absorbent band that also discloses the eplerenone in the chloroformic solution is with as a comparison.Observed the difference between form H and crystalline form L or the butanone compound, for example, the district has observed difference at the spectrographic carbonyl.The ester carbonyl group drawing zone of form H is at about 1739cm
-1, and crystalline form L and butanone compound are respectively about 1724 and 1722cm
-1Has corresponding stretching.Eplerenone in chloroformic solution is at about 1727cm
-1Produce the stretching of ester carbonyl group.The variation of the stretching frequency of ester carbonyl group has reflected the variation of the ester group orientation between these two kinds of crystalline forms between form H and the crystalline form L.In addition, in the A cyclopentanoperhydro-phenanthrene stretching of the ester of conjugation ketone from about 1664-1667cm of form H or butanone compound
-1Be moved to about 1665cm of crystalline form L
-1Corresponding carbonyl stretches and occurs in about 1665cm in chloroformic solution
-1
Another difference between form H and the crystalline form L sees the C-H buckled zone.Form H is at about 1399cm
-1Absorption is arranged, and this does not observe in crystalline form L, butanone compound or the eplerenone in chloroformic solution.This 1399cm
-1Stretching occurs in the C2 of contiguous carbonyl and the CH of C21 methylene radical
2The shear zone.
Table 2: the IR absorption band (cm of eplerenone form
-1)
| The absorption region | Form H | Crystalline form L | The butanone compound | Chloroformic solution |
| ν C=O (lactone) | 1773 | ?1775 | ?1767 | ?1768 |
| ν C=O (ester) | 1739 | ?1724 | ?1722 | ?1727 |
| ν C=O (3-ketone group) | 1664 | ?1655 | ?1667 | ?1665 |
| ν C=C (3,4-alkene) | 1619 | ?1619 | ?1622 | ?1623 |
| ?δ asCH 3，δCH 2， ?δCH 2(the α position of carbonyl) | 1460，1444， 1426 | ?1467，1438， ?1422，1399 | ?1467，1438， ?1422 | ?1464，1438， ?1422 |
| ?δ sCH 3 | 1380 | ?1381 | ?～1380 | ?1378 |
Accompanying drawing 39-51 has shown the example of infrared absorption spectrum of the solvation crystalline form of following eplerenone respectively: n-propyl alcohol compound, tetrahydrofuran (THF) compound, ethyl propionate compound, acetone compound, toluene compound, Virahol compound, ethanol compound, isobutyl acetate compound, butylacetate compound, propyl acetate compound, methyl acetate compound, propylene glycol compound and tert.-butyl acetate compound.
5. nucleus magnetic resonance (NMR) spectrum
Obtain in 31.94 districts
13C NMR spectrum.Eplerenone crystalline form H and crystalline form L's
13C NMR spectrographic example is respectively shown in accompanying drawing 52 and 53.By analyzing the data of eplerenone crystalline form H, found that eplerenone crystalline form H is not mutually pure and contains eplerenone crystalline form L in a small amount to obtain in Figure 52, to reflect.Form H makes it the most clearly be different from other form by the carbon resonance around 64.8ppm, 24.7ppm and 19.2ppm.Crystalline form L makes it the most clearly be different from other form by the carbon resonance around 67.1ppm and 16.0ppm.
6. thermogravimetry
Carry out thermogravimetric analysis with TA Instruments TGA 2950 thermogravimeters.Under the nitrogen flushing, sample is placed untight aluminum pot.Starting temperature is 25 ℃, and temperature heats up with about 10 ℃/minute speed.Accompanying drawing 54-71 has shown the example of thermogravimetry analysis chart of the solvation crystalline form of following eplerenone respectively: be respectively the butanone compound, the n-propyl alcohol compound, the tetrahydrofuran (THF) compound, the ethyl propionate compound, the acetate compound, the chloroform compound, the acetone compound, the toluene compound, the Virahol compound, the ethanol compound, the isobutyl acetate compound, the n-butyl acetate compound, the methyl acetate compound, the propyl acetate compound, the propylene glycol compound, the propyl carbinol compound, n-Octanol compound and tert.-butyl acetate compound.
7. microscopy
8. unit cell parameters
Following table 3A, 3B and 3C have summed up the unit cell parameters of form H, crystalline form L and several eplerenone solvation crystalline forms measured.
Table 3A: the unit cell parameters of eplerenone crystalline form
| Parameter | Form H | Crystalline form L | The butanone compound |
| Crystallographic system | Quadrature | Monocline | Quadrature |
| Spacer | ? | ?P2 1 | ? |
| a | ?21.22 | ?8.78 | ?23.53 |
| b | ?15.40 | ?11.14 | ?8.16 |
| c | ?6.34 | ?11.06 | ?13.08 |
| α | ?90° | ?90° | ?90° |
| β | ?90° | ?93.52° | ?90° |
| γ | ?90° | ?90° | ?90° |
| Z | ?4 | ?2 | ?4 |
| Volume () | ?2071.3 | ?1081.8 | ?2511.4 |
| Parameter | Form H | Crystalline form L | The butanone compound |
| ρ (calculated value) | 1.329g/cm 3 | 1.275g/cm 3 | 1.287g/cm 3 |
| R | 0.0667 | 0.062 | 0.088 |
Table 3B: the unit cell parameters of eplerenone crystalline form
| Parameter | The acetone compound | The toluene compound | The butylacetate compound 1 |
| Crystallographic system | Quadrature | Quadrature | Quadrature |
| Spacer | ? | ? | ? |
| ?a | ?23.31 | ?23.64 | ?23.07 |
| ?b | ?13.13 | ?13.46 | ?13.10 |
| ?c | ?8.28 | ?8.16 | ?8.24 |
| ?α | ?90° | ?90° | ?90° |
| ?β | ?90° | ?90° | ?90° |
| ?γ | ?90° | ?90° | ?90° |
| ?Z | ?4 | ?4 | ?4 |
| Volume () | ?2533.7 | ?2596.6 | ?2490.0 |
| ρ (calculated value) | ?1.239g/cm 3 | ?1.296g/cm 3 | ?1.334g/cm 3 |
| ?R | ?0.058 | ?0.089 | ?0.093 |
1Because the disorder of solvent molecule in the passage, butylacetate adduct molecule are thoroughly not refining.
Table 3C: the unit cell parameters of eplerenone crystalline form
| Parameter | The isobutyl acetate compound 1 | The Virahol compound 1 | The ethanol compound 1 |
| Crystallographic system | Quadrature | Quadrature | Quadrature |
| Spacer | ? | ? | ? |
| a | ?23.19 | ?23.15 | ?23.51 |
| b | ?12.95 | ?12.73 | ?13.11 |
| c | ?8.25 | ?8.25 | ?8.27 |
| α | ?90° | ?90° | ?90° |
| β | ?90° | ?90° | ?90° |
| γ | ?90° | ?90° | ?90° |
| Z | ?4 | ?4 | ?4 |
| Volume () | ?2476.4 | ?2433.2 | ?2548.6 |
| ρ (calculated value) | ?1337g/cm 3 | ?1.296g/cm 3 | ?1.234g/cm 3 |
| R | ?0.098 | ?0.152 | ?0.067 |
1Because the disorder of solvent molecule in the passage, solvate molecule are thoroughly not refining.
Out of Memory to selected eplerenone solvation crystalline form is reported in following table 4.The structure cell data of the butanone compound of reporting among the last table 3A have also been represented the unit cell parameters of a lot of other eplerenone recrystallisation solvent compounds.Tested most of eplerenone recrystallisation solvent compounds are isomorphism each other basically.Though owing to mix varying in size of solvent molecule, a kind of solvation crystalline form and another kind of some very little displacements of existence in X-ray powder diffraction peak, but whole diffractogram is substantially the same, and unit cell parameters is consistent basically for most of solvates of testing with the molecule position.
Table 4: about the out of Memory of eplerenone solvate
| Solvent | Stoichiometry solvent: eplerenone | With butanone compound isomorphism whether? | The desolvation temperature 1(℃) |
| | 1∶1 | 89 | |
| | 1∶2 | Be | 203 |
| | 1∶1 | Be | 117 |
| | 1∶1 | Be | 103 |
| | 1∶1 | Be | 130 |
| | 1∶2 | Be | 108 |
| | 1∶2 | Be | 112 |
| Tert.-butyl acetate | --- | Be | 109 |
| Chloroform | --- | Be | 125 |
| | 1∶1 | Be | 166 |
| N- | 1∶2 | Be | 129 |
| | 1∶1 | Be | 121 |
| | 1∶1 | Be | 103 |
| N-Octanol | --- | Be | 116 |
| | 1∶1 | Be | 122 |
| Propylene glycol | --- | Be | 188 |
| Tetrahydrofuran (THF) | 1∶1 | Be | 136 |
| | 1∶1 | Be | 83 |
1Be defined as from the desolvation temperature of final weight of solvent loss step extrapolation, this is to measure under nitrogen wash with 10 ℃/minute rate of heating by thermogravimetric analysis.But the desolvation temperature may be subjected to solvate preparation method's influence.Diverse ways may produce the nucleogenesis site of different quantities, and this site can cause the desolvation of solvate at lesser temps.
The structure cell of solvate is by 4 eplerenone molecular compositions.For multiple solvate, eplerenone molecule and the solvent molecule stoichiometry in this structure cell also is reported in table 4.The form H structure cell is by 4 eplerenone molecular compositions.Crystalline form L structure cell is by two eplerenone molecular compositions.When eplerenone molecule crystalline form migration and rotation during with the space filling up solvent molecule and stay, the solvate structure cell changes form H and/or crystalline form L structure cell in the desolvation process.Table 4 has also been reported the desolvation temperature of a lot of different solvents things.
9. the crystallographic property of impurity
In the desolvation process of solvate, selected impurity can be induced the formation of form H in eplerenone.Particularly estimate the effect of following two kinds of impurity molecules: 4 α, 5 α; 9 α, 11 α-diepoxy-17-hydroxyl-3-oxo-17 alpha-pregnane-7 α, 21-dioctyl phthalate hydrogen 7-methyl esters, gamma lactone (III) (" diepoxide "); With 11 α, 12 alpha-epoxy-17s-hydroxyl-3-oxo-17 α-pregnant-4-alkene-7 α, 21-dioctyl phthalate hydrogen 7-methyl esters, gamma lactone (IV) (" 11, the 12-epoxide ").
These impurity molecules are described in more detail to acting among this paper embodiment of desolvation gained eplerenone crystalline form.
Because 17-hydroxyl-3-oxo-17 α-pregnant-4,9 (11)-diene-7 α, 21-dioctyl phthalate hydrogen 7-methyl esters, the single crystal structure and the form H eplerenone of gamma lactone (V) (" 9; 11-alkene ") are similar, therefore our supposition is during the desolvation of solvate 9, and 11-alkene also can be induced the formation of form H.
The monocrystalline that separates every kind of impurity compound.Isolating diepoxide, 11,12-epoxide and 9, the representative X-ray powder diffraction pattern of 11-alkene crystalline form is respectively shown in accompanying drawing 74,75 and 76.The X-ray powder diffraction pattern of every kind of impurity molecule is similar to the X-ray powder diffraction pattern of form H, and this shows that three kinds of impurity compounds of form H and this have similar single crystal structure.
The monocrystalline that has also separated every kind of impurity compound, and carry out the X-ray structure and measure to confirm that the single crystal structure that these three kinds of compounds adopt is similar to form H.The monocrystalline that from butanone, separates this diepoxide.From Virahol, separate 11, the monocrystalline of 12-epoxide.From propyl carbinol, separate 9, the monocrystalline of 11-alkene.The crystalline structure gained data of measuring every kind of impurity compound crystalline form are as shown in table 5.To form H, diepoxide, 11,12-epoxide and 9, the gained crystallographic system of 11-alkene crystalline form is identical with unit cell parameters basically.
Table 5: compare eplerenone crystalline form H and impurity crystalline unit cell parameters
| Parameter | Form H | Diepoxide | 11, the 12-epoxide | 9,11-alkene |
| Crystallographic system | Quadrature | Just become | Quadrature | Quadrature |
| Spacer | ? | ? | ? | ? |
| a | ?21.22 | ?21.328 | ?20.90 | ?20.90 |
| b | ?15.40 | ?16.16 | ?15.55 | ?15.74 |
| c | ?6.34 | ?6.15 | ?6.38 | ?6.29 |
| α | ?90° | ?90° | ?90° | ?90° |
| β | ?90° | ?90° | ?90° | ?90° |
| γ | ?90° | ?90° | ?90° | ?90° |
| Parameter | Form H | Diepoxide | 11, the 12-epoxide | 9,11-alkene |
| Z | ?4 | ?4 | ?4 | ?4 |
| Volume () | ?2071.3 | ?2119.0 | ?2073.2 | ?2069.3 |
| ρ (calculated value) | ?1.329g/cm 3 | ?1.349g/cm 3 | ?1.328g/cm 3 | ?1.279g/cm 3 |
| R | ?0.0667 | ?0.0762 | ?0.0865 | ?0.0764 |
4 kinds of compound crystals of report become identical spacer in the table 5, and have similar unit cell parameters (being that they are isomorphisms).Suppose this diepoxide, 11,12-epoxide and 9,11-alkene adopts the form H conformation.For every kind of impurity compound, relatively easily separate form H filler (directly from solution), this shows that the form H lattice is stable filling mode in the similar compound of this series structure.Therefore, the doping agent that all can be used as crystallization eplerenone crystalline form H from solution with any compound of eplerenone crystalline form H crystallography isomorphism.
Therefore, in a particular, the invention provides the method for crystallization eplerenone crystalline form H from the solution of eplerenone in solvent or solvent mixture, described method is included in before the crystallization with significant quantity and compound doped this solution eplerenone crystalline form H crystallography isomorphism.Should be appreciated that " doping " in this article can be initiatively, add doped compound in the solution that promptly has a mind, or passive, promptly this doping is owing to exist in the solution as due to the doped compound of impurity.
According to this embodiment, preferred doped compound is a diepoxide, 11,12-epoxide and 9, and 11-alkene promptly is respectively top compound (III), (IV) and (V).
The preparation eplerenone
The eplerenone raw material that is used to prepare the new crystalline form of the present invention can pass through currently known methods own, is included in the method that provides among above-mentioned international monopoly publication WO 97/21720 and the WO 98/25948, and the scheme 1 that particularly provides in the two makes.
The preparation crystalline form
1. prepare the solvation crystalline form
The solvation crystalline form of eplerenone can prepare by crystallization eplerenone from the mixture of The suitable solvent or suitable solvent.The mixture of The suitable solvent or suitable solvent generally comprises the such organic solvent or the mixture of organic solvent, and it dissolves eplerenone and any impurity at elevated temperatures, preferential crystallization solvate when still cooling off.Under the room temperature in the mixture of these solvents or solvent the solubleness of eplerenone be generally the about 200mg/mL of about 5-.These solvents or solvent mixture are preferably selected from used solvent in the process of preparation eplerenone raw material, if be pharmaceutically useful solvent when particularly being included in the final pharmaceutical composition that contains eplerenone crystalline form.For example, the solvent systems that contains methylene dichloride that obtains containing the solvate of methylene dichloride generally is worthless.
Used each solvent is acceptable solvent preferably, particularly at " impurity: residual solvent guide ", 2 classes or 3 kind solvents of definition in the international conference (InternationalConference On Harmonisation Of Technical Requirements ForRegistration Of Pharmaceuticals For Human Use) (step 4 that ICH steering committee was recommended in the ICH program on July 17th, 1997 adopts) are coordinated in human drug legislation technical requirements.More preferably, these solvents or solvent mixture are selected from butanone, 1-propyl alcohol, 2 pentanone, acetate, acetone, butylacetate, chloroform, ethanol, isopropylcarbinol, isobutyl acetate, methyl acetate, ethyl propionate, propyl carbinol, n-Octanol, Virahol, propyl acetate, propylene glycol, the trimethyl carbinol, tetrahydrofuran (THF), toluene, methyl alcohol and tert.-butyl acetate.More preferably, described solvent is selected from butanone and ethanol.
In another embodiment of this method, described solvent or solvent mixture are selected from 1-propyl alcohol, 2 pentanone, acetate, acetone, butylacetate, chloroform, isopropylcarbinol, isobutyl acetate, methyl acetate, ethyl propionate, propyl carbinol, n-Octanol, propyl acetate, propylene glycol, the trimethyl carbinol, tetrahydrofuran (THF), toluene, methyl alcohol and tert.-butyl acetate.
In another embodiment of this method, described solvent or solvent mixture are selected from 1-propyl alcohol, 2 pentanone, acetate, acetone, butylacetate, chloroform, isopropylcarbinol, isobutyl acetate, methyl acetate, ethyl propionate, propyl carbinol, n-Octanol, propyl acetate, propylene glycol, the trimethyl carbinol, tetrahydrofuran (THF), toluene, methyl alcohol and tert.-butyl acetate.
In order to prepare the solvation crystalline form of eplerenone, in the solvent of certain volume, and cooling is until forming crystal with a certain amount of eplerenone material dissolution.Solvent temperature when adding eplerenone in solvent generally is to select according to the solubility curve of this solvent or solvent mixture.For most of solvents described herein, for example this solvent temperature is generally at least about 25 ℃, and the boiling temperature of preferred about 30 ℃-this solvent more preferably is lower than the boiling temperature of the about 25 ℃ temperature of this solvent boiling point-this solvent.
Perhaps, hot solvent can be added in the eplerenone, and can be with this mixture cooling until forming crystal.Solvent temperature when adding solvent in eplerenone generally is to select according to the solubility curve of this solvent or solvent mixture.For most of solvents described herein, for example this solvent temperature is generally at least about 25 ℃, and the boiling temperature of preferred about 50 ℃-this solvent more preferably is lower than the boiling temperature of the about 15 ℃ temperature of this solvent boiling point-this solvent.
Depend on the solubility curve of this solvent or solvent mixture equally with the amount of the eplerenone raw material of the solvent of given volume.Generally speaking, the amount that is added to the eplerenone in the solvent at room temperature can not be dissolved in the solvent of this volume fully.For most of solvents described herein, for example with the amount of the eplerenone raw material of the solvent of given volume be generally when the room temperature can solvent at this volume in the dissolved eplerenone amount at least about about 4.0 times of 1.5-, be preferably about 3.5 times of about 2.0-, more preferably about 2.5 times.
When the eplerenone raw material has been dissolved in the solvent fully, usually this solution is cooled off lentamente the solvation crystalline form that goes out eplerenone with crystallization.For most of solvents described herein, for example be lower than about 20 ℃/minute speed, preferably with about 10 ℃/minute or lower speed, more preferably with about 5 ℃/minute or lower speed, also more preferably cool off this solution with about 1 ℃/minute or lower speed.
The terminal temperature of results solvation crystalline form depends on the solubility curve of solvent or solvent mixture.For most of solvents described herein, for example this terminal temperature be generally be lower than about 25 ℃, preferably be lower than about 5 ℃, more preferably less than-5 ℃ approximately.Reduce the formation that this terminal temperature helps the solvation crystalline form usually.
Perhaps, can use other technology to prepare solvate.The example of such technology include but not limited to (i) with the eplerenone material dissolution in a kind of solvent, and the adding solubility promoter promotes the crystallization of solvation crystalline form, the (ii) vapor diffusion of solvate growth, (iii) rotary evaporation separates solvate and (iv) slurries conversion by for example evaporating.
Can for example filter by the conventional means of any appropriate or the crystal of the centrifugal solvation crystalline form that will make is as mentioned above separated from solvent.The stirring that improves solvent systems during crystallization causes generating the littler crystal of particle diameter usually.
2. prepare crystalline form L from solvate
Eplerenone crystalline form L can directly be made by the solvation crystalline form by desolvation.Can be by the desolvation means of any appropriate, such as but not limited to environmental stress around solvate heating, the reduction solvate or the combination of the two are realized desolvation.If the solvate heating is for example heated to remove in baking oven to desolvate, generally is no more than the change invert point of form H and crystalline form L in the temperature of this operating period.This temperature preferably is no more than about 150 ℃.
Desolvation pressure and desolvation time are also not really important.Desolvation pressure is preferably about 1 normal atmosphere or lower.Yet, when reducing desolvation pressure, to reduce equally and can carry out desolvated temperature and/or desolvation time.Particularly for the solvate with higher desolvation temperature, vacuum-drying makes can adopt lower drying temperature.Only need to be enough to desolvation to form the desolvation time of crystalline form L.
In order to guarantee to make the product of all being made up of crystalline form L basically, the eplerenone raw material generally is the high purity eplerenone, is pure eplerenone basically preferably.The eplerenone raw material that is used to prepare eplerenone crystalline form L generally has at least 90% purity, preferred at least 95 purity, more preferably at least 99% purity.As discussing in the application other places, some impurity in the eplerenone raw material may cause disadvantageous effect to productive rate and the crystalline form L content by this method products therefrom.
The eplerenone crystallized product that makes by high purity eplerenone raw material by this method generally comprise at least 10% crystalline form L, preferred at least 50% crystalline form L, more preferably at least 75% crystalline form L, also more preferably at least 90% crystalline form L, more more preferably at least about 95% crystalline form L, further more preferably be mutually pure crystalline form L basically.
3. prepare form H by solvate
The product that can comprise form H according to identical with above-mentioned crystalline form L preparation method basically method preparation, and (i) use low-purity eplerenone raw material to replace high purity eplerenone raw material, (ii) in solvent systems, add mutually pure form H crystalline crystal seed, perhaps unite use (i) and (ii).
3.1 use impurity as crystal growth promoters and inhibitor
In the eplerenone raw material, have selected impurity and its content, rather than the total amount of all impurity influences form H crystalline formation potentiality in the eplerenone during the desolvation of solvate.Selected impurity generally is form H growth stimulant or crystalline form L growth inhibitor.Selected impurity can be included in the eplerenone raw material, is included in (before adding the eplerenone raw material) in solvent or the solvent mixture, and/or is added to (after adding the eplerenone raw material) in solvent or the solvent mixture.People such as Bonafede (1995), " by the selectivity nucleogenesis and the growth of organic polymorphic form of the extension of outstanding guiding on the molecular crystal substrate ", J.Amer.Chem.Soc., 117 (30) (introducing the present invention with for referencial use) have been discussed and used growth stimulant and growth inhibitor in the polymorphic form systems.For the present invention, suitable impurity generally comprises the compound with single crystal structure substantially the same with the single crystal structure of eplerenone crystalline form H.Impurity is preferably its X-ray powder diffraction pattern compound substantially the same with the X-ray powder diffraction pattern of eplerenone crystalline form H, more preferably is selected from diepoxide, 11,12-epoxide, 9,11-alkene and their combination.
The amount of the impurity that preparation form H crystal is required generally depends in part on solvent or solvent mixture and the impurity solubleness with respect to eplerenone.When crystalline form H from butanone solvent, for example the weight ratio of diepoxide and low-purity eplerenone raw material be generally at least about 1: 100, be preferably at least about 3: 100, more preferably about 3: about 1: 5 of 100-, also more preferably about 3: about 1: 10 of 100-.11, the solubleness of 12-epoxide in butanone is than diepoxide height, and in order to prepare eplerenone crystalline form H crystal, need usually more substantial 11, the 12-epoxide.When impurity comprises 11, during the 12-epoxide, the weight ratio of this diepoxide and low-purity eplerenone raw material is generally at least about 1: 5, more preferably about 3: 25, also more preferably about 3: about 1: 5 of 25-.When not only using diepoxide but also use 11 in preparation form H crystalline process, during 12-epoxide impurity, the weight ratio of every kind of impurity and eplerenone raw material can be lower than the corresponding ratio when only using a kind of impurity in preparation form H crystalline process.
When handle comprises the solvate desolvation of selected impurity, can obtain the mixture of eplerenone crystalline form H and crystalline form L usually.By solvate being begun in the product that desolvation obtains, the weight fraction of form H is generally and is lower than about 50%.As described below by crystallization or boiling this product is further handled after, the weight fraction of crystalline form L generally can increase in the product.
3.2 adding crystal
The form H crystal can make by the crystal seed (or aforesaid form H growth stimulant and/or crystalline form L growth inhibitor) that added mutually pure form H before the crystallization eplerenone in solvent systems.The eplerenone raw material can be low-purity eplerenone or high purity eplerenone.When the solvate desolvation that made by any raw material, the weight fraction of form H in product is generally at least about 70% and can be greatly to about 100%.
Be added to form H crystal seed and the weight ratio that is added to the eplerenone raw material in the solvent systems in the solvent systems be generally at least about 0.75: 100, be preferably about 0.75: about 1: 20 of 100-, more preferably about 1: about 1: 50 of 100-.The form H crystal seed can by describe among the application about preparation form H crystalline any means, particularly as described belowly prepare form H crystalline method by boiling and make.
The form H crystal seed can disposablely add, adds several times or adds substantially continuously through for some time.Yet, begin from solution, to finish before the crystallization adding of form H crystal seed usually in eplerenone, promptly reaching the preceding crystal seed that adds fully of cloud point (metastable zone hangs down terminal point).General when solution temperature be more than the cloud point about 0.5 ℃-about 10 ℃, adding crystal seed when being preferably more than the cloud point about 2 ℃-Yue 3 ℃ more than the cloud point.When the temperature more than the cloud point when adding crystal seed increased, the required crystal seed add-on of crystalline form H crystal was generally increase.
Add crystal seed and preferably not only can more than cloud point, carry out, and can in metastable zone, carry out.Cloud point and metastable zone all depend on solubleness and the concentration of eplerenone in solvent or solvent mixture.For example, for 12 volume dilution of butanone, the high terminal point of metastable zone is generally about 70 ℃-Yue 73 ℃, and metastable zone hangs down terminal point (being cloud point) and is about 57 ℃-Yue 63 ℃.For the concentration of 8 volume butanone, metastable zone is much narrow, and this is because due to the solution supersaturation.Under this concentration, the cloud point of this solution is about 75 ℃-Yue 76 ℃.Because the boiling point of butanone is about 80 ℃ under envrionment conditions, so generally in this solution, add crystal seed about 76.5 ℃-this boiling temperature.
This paper embodiment 7 has provided the limiting examples that adds the form H crystal seed.
With form H growth stimulant or crystalline form L growth inhibitor and/or add eplerenone crystallized product that the form H crystal seed obtained generally comprise at least 2% form H, preferably at least 5% form H, more preferably at least 7% form H, also more preferably at least about 10% form H.Remaining eplerenone crystallized product is generally to be crystalline form L.
3. prepare form H by grinding eplerenone
In another embodiment, have been found that a spot of form H can make by suitably grinding eplerenone.Observe, in the eplerenone of grinding, the concentration of form H is up to about 3%.
4. prepare crystalline form L from the solvate that makes by the low-purity eplerenone
As mentioned above, crystallization low-purity eplerenone generally can make the product that comprises form H and crystalline form L with this solvate desolvation then to form solvate.According to the method substantially the same with the mode of above-mentioned preparation form H, by in solvent systems, adding mutually pure crystalline form L crystal seed, or, can make product by the low-purity eplerenone with big crystalline form L content by using crystalline form L growth stimulant and/or form H growth inhibitor.The amount that adds the scheme of crystal seed and be added to the crystalline form L crystal seed in the solvent systems be added to solvent systems in the weight ratio of amount of eplerenone raw material with above similar about preparing the described weight ratio of eplerenone crystalline form H by the mutually pure form H crystal seed of adding.
The eplerenone crystallized product that makes with this method generally comprise at least 10% crystalline form L, preferred at least 50% crystalline form L, more preferably at least 75% crystalline form L, more preferably at least 90% crystalline form L, also more preferably at least about 95% crystalline form L, further more preferably be mutually pure crystalline form L basically.
Adding crystal seed scheme about preparation eplerenone crystalline form H described herein also can be used for improving the control of crystalline eplerenone particle diameter.
5. direct crystallization crystalline form L from solution
Eplerenone crystalline form L also can make by direct crystallization eplerenone from suitable solvent or solvent mixture, and need not form the solvate intermediate and the desolvation that needs of following.Generally speaking, (i) solvent have with the solvate lattice in the inconsistent molecular size in available channel space, (ii) existing any impurity of eplerenone can be dissolved in this solvent at elevated temperatures, and (iii) cooling causes crystallization to go out the eplerenone crystalline form L of non-solventization.At room temperature, the solubleness of eplerenone in solvent or solvent mixture is generally the about 200mg/ml of about 5-.Described solvent or solvent mixture preferably comprise one or more solvents that is selected from methyl alcohol, ethyl acetate, isopropyl acetate, acetonitrile, oil of mirbane, water and ethylbenzene.
For directly from solution crystallization go out eplerenone crystalline form L, in the solvent of certain volume, and cooling is until forming crystal with a certain amount of eplerenone material dissolution.Solvent temperature when adding eplerenone in solvent generally is to select according to the solubility curve of this solvent or solvent mixture.For most of solvents described herein, this solvent temperature is generally at least about 25 ℃, and the boiling temperature of preferred about 30 ℃-this solvent more preferably is lower than the boiling temperature of the about 25 ℃ temperature of this solvent boiling point-this solvent.
Perhaps, hot solvent can be added in the eplerenone, and can be with this mixture cooling until forming crystal.Solvent temperature when adding solvent in eplerenone generally is to select according to the solubility curve of this solvent or solvent mixture.For most of solvents described herein, this solvent temperature is generally at least about 25 ℃, and the boiling temperature of preferred about 50 ℃-this solvent more preferably is lower than the boiling temperature of the about 15 ℃ temperature of this solvent boiling point-this solvent.
Depend on the solubility curve of this solvent or solvent mixture equally with the amount of the eplerenone raw material of the solvent of given volume.Generally speaking, the amount that is added to the eplerenone in the solvent at room temperature can not be dissolved in the solvent of this volume fully.For most of solvents described herein, with the amount of the eplerenone raw material of the solvent of given volume be generally when the room temperature can solvent at this volume in the dissolved eplerenone amount at least about about 4.0 times of 1.5-, be preferably about 3.5 times of about 2.0-, for example be about 2.5 times.
In order to guarantee to make the product that comprises mutually pure basically crystalline form L, the eplerenone raw material generally is a high-purity raw.The eplerenone raw material preferably has at least about 65% purity, more preferably has at least about 90% purity, also more preferably has at least about 98% purity, most preferably has at least about 99% purity.
When the eplerenone raw material has been dissolved in the solvent fully, usually this solution is cooled off lentamente with crystallization and go out eplerenone crystalline form L.For most of solvents described herein, for example be lower than about 1 ℃/minute speed, preferably with about 0.2 ℃/minute or lower speed, more preferably cool off this solution with about 0.05 ℃/minute-Yue 0.1 ℃/minute speed.
The terminal temperature of results crystalline form L depends on the solubility curve of solvent or solvent mixture.For most of solvents described herein, this terminal temperature be generally be lower than about 25 ℃, preferably be lower than about 5 ℃, more preferably less than-5 ℃ approximately.
Perhaps, can use other technology to prepare solvate.The example of such technology include but not limited to (i) with the eplerenone material dissolution in a kind of solvent, and the adding solubility promoter promotes the crystallization of eplerenone crystalline form L, the (ii) vapor diffusion of eplerenone crystalline form L growth, (iii) by for example evaporate rotary evaporation isolate eplerenone crystalline form L and (iv) slurries transform.
Can for example filter by the conventional means of any appropriate or the crystal of the centrifugal eplerenone crystalline form L that will make is as mentioned above separated from solvent.
In addition, eplerenone crystalline form L can pass through the slurries boiling (as described below) of high purity eplerenone in butanone, and the eplerenone of filtration boiling under the boiling temperature of these slurries makes.
6. from solution, directly prepare form H
According to supposition, if at the change transition temperature (T of form H and crystalline form L
t) more than carry out crystallization, if particularly have form H growth stimulant or crystalline form L growth inhibitor or add mutually pure form H crystal seed, form H will directly crystallize out from solution, this is because form H more stable cause under these higher temperature conditions.The preferred solvent systems that uses comprises for example oil of mirbane of high boiling solvent.Suitable form H growth stimulant includes but not limited to aforesaid diepoxide and 11,12-alkene.
7. with solvent boiling eplerenone
The solvation crystalline form of eplerenone, form H and crystalline form L also can be by making the boiling in suitable solvent or solvent mixture of eplerenone raw material.In this boiling method, the eplerenone slurries heat under solvent or solvent mixture boiling point.For example, solvent or solvent mixture merging with a certain amount of eplerenone raw material and certain volume are heated to backflow, remove distillate, add certain amount of solvent simultaneously again and remove distillate.Perhaps, can and recycle, just need not add solvent more in addition in boiling operating period like this distillate condensation.Generally speaking, in case the solvent of original volume has been removed or condensation and circulation, is about to the slurries cooling, and has formed the solvation crystalline form.Can for example filter or centrifugal crystal with solvation is separated from solvent by any conventional means.Still there is not selected impurity according to existing in the crystal of this solvation, as mentioned above the solvate desolvation can be generated eplerenone crystalline form H or crystalline form L.
Suitable solvent or solvent mixture generally comprise one or more above-mentioned solvents.Solvent can be selected from for example butanone and ethanol.
In the boiling operation, the amount that is added to the eplerenone raw material in the solvent for use generally is the amount that is enough to keep slurries (being that eplerenone can not be dissolved fully) under the boiling temperature of this solvent or solvent mixture in solvent or solvent mixture.For example, in about 0.25g/ml butanone or the eplerenone concentration in about 0.125g/ml ethanol be operable.
In case after the solvent turnover (turnover) fully, promptly slurries are cooled off the solvation crystalline form that goes out eplerenone with crystallization lentamente usually.For test solvent, be lower than about 20 ℃/minute, preferred about 10 ℃/minute or lower, more preferably from about 5 ℃/minute or lower, also more preferably from about 1 ℃/minute or lower speed are cooled off this slurries.
The terminal temperature of results solvation crystalline form depends on the solubility curve of solvent or solvent mixture.For most of solvents described herein, this terminal temperature be generally be lower than about 25 ℃, preferably be lower than about 5 ℃, more preferably less than-5 ℃ approximately.
Mainly comprise or only comprise the product of crystalline form L if desired, usually with high purity eplerenone material cooking.Described high purity eplerenone raw material preferably have at least about 98% purity, more preferably at least about 99% purity, also more preferably at least about 99.5% purity.The eplerenone boiling product that makes in this mode generally comprise at least about 10% crystalline form L, preferably at least about 50% crystalline form L, more preferably at least about 75% crystalline form L, also more preferably at least about 90% crystalline form L, more more preferably at least about 95% crystalline form L, most preferably be mutually pure crystalline form L basically.
Mainly comprise or only comprise the product of form H if desired, usually with low-purity eplerenone material cooking.Low-purity eplerenone raw material comprises usually in order to generate the form H growth stimulant and/or the crystalline form L growth inhibitor of the minimum necessary amounts of form H.This low-purity eplerenone raw material preferably have at least about 65% purity, more preferably at least about 75% purity, also more preferably at least about 80% purity.The eplerenone boiling product that makes in this mode generally comprise at least about 10% form H, preferably at least about 50% form H, more preferably at least about 75% form H, also more preferably at least about 90% form H, more more preferably at least about 95% form H, most preferably be mutually pure form H basically.
8. prepare amorphous eplerenone
Amorphous eplerenone can be passed through the suitable pulverizing of eplerenone solid, for example by crushing, grinding and/or micronization the eplerenone solid is pulverized on a small quantity to make.Mutually pure amorphous eplerenone, promptly being substantially free of the amorphous eplerenone of eplerenone crystalline can be by for example making eplerenone solution, the particularly lyophilize of the eplerenone aqueous solution.This paper embodiment 13 and 14 for example understands these methods.
Other processes consideration
1. thermodynamic stability is considered
In room temperature, crystalline form L is more stable on thermodynamics than form H.As described in this paper embodiment 5, when being placed in room temperature, the organic slurry that contains equivalent form H and crystalline form L spends the night, and to collect residual solid then and pass through the X-ray powder diffraction when analyzing, analytical results shows that eplerenone has changed into crystalline form L fully.Above the dsc of Miao Shuing (DSC) data show that form H is more stable on thermodynamics than crystalline form L under comparatively high temps, and this is because form H has due to higher fusing/decomposition temperature.Slurries transform and the DSC data show that together form H is that change is relevant with crystalline form L, promptly at transition temperature (T
t) near, can change in the stability contact between these two kinds of polymorphic forms, crystalline form L is more stable at a lower temperature.Accompanying drawing 77 expression be for the relevant polymorphic form of change for example eplerenone crystalline form H and crystalline form L, the relation between Gibbs free energy and the temperature, wherein T
tBe meant transition temperature and T
mBe meant the fusing point of form H and crystalline form L.
Therefore, comprise in preparation during the composition of crystalline form L, processing temperature preferably remains on below the transition temperature.For example, the drying temperature that desolvation adopted generally be lower than about 150 ℃, preferably be lower than about 125 ℃, more preferably less than about 115 ℃, more preferably less than about 110 ℃, also more preferably about 80 ℃-Yue 110 ℃.In addition, during particle diameter reduces procedure of processing,, may must cool off (for example using liquid nitrogen to cool off) for crystalline form L crystalline temperature is remained on below the transition temperature.
2. inner micronization is considered
Be used to prepare the character that eplerenone crystalline method may influence resulting crystalline forms.For example, and compare, in lattice, show higher surface damage, hole, crack and fracture incidence by the crystalline form L that the solvate desolvation is made by the crystalline form L that directly crystallization makes from solution.Desolvated crystalline this " inner micronization " causes crystalline effective surface and crystalline dissolution rate all to increase.Therefore, dissolution time can shorten by the crystalline form L crystal of selection via the desolvation preparation, prolong by the crystalline form L crystal of selection, perhaps by selecting to regulate dissolution time with the crystalline form L crystalline appropriate combination for preparing via direct crystallization via the crystalline form L crystal of desolvation preparation via the direct crystallization preparation.
When using the crystalline form L crystal pharmaceutical compositions that makes by desolvation, inner micronization can also reduce or eliminate the needs that reduce crystal particle diameter during procedure of processing effectively.Yet using shortcoming of such crystalline form L crystalline is to need the desolvation step, and this is unwanted for the crystalline form L crystal that makes by direct crystallization.
The solid-state form of the product that makes by the inventive method
Embodiment of the present invention also comprises special solid-state eplerenone form and the combination thereof that makes according to the disclosed method of the application.Particularly, the eplerenone crystalline form H that makes according to the described method of the application separately or the combination of itself and one or more other solid-state form (comprising solvation crystalline form, crystalline form L and amorphous eplerenone) be embodiment of the present invention.In addition, be embodiment of the present invention as the solvation crystalline form for preparing the intermediate of eplerenone crystalline form H by desolvation and make according to the described method of the application.
The combination of solid-state form
In the combination that comprises first kind of solid-state form eplerenone and second kind of solid-state form eplerenone, wherein said first kind and second kind of solid-state form eplerenone are selected from the eplerenone and the amorphous eplerenone of form H, crystalline form L, solvation, and first kind of any appropriate weight ratio with second kind of solid-state form all is spendable.In such combination, first kind of weight ratio with second kind of solid-state form is preferably about 1 usually: about 99: 1 of 99-, more preferably at least about 1: 9, more preferably at least about 1: 1, more preferably at least about 2: 1, more preferably at least about 5: 1, most preferably be at least about 9: 1.
According to embodiment of the present invention, first kind of solid-state form is form H, and second kind of solid-state form is crystalline form L.
In another embodiment, also there is the third solid-state form.
The eplerenone particle diameter
Though the eplerenone of every kind of above-mentioned solid-state form and combination thereof can comprise the eplerenone particle diameter of wide region, have been found that the D that the particle diameter of solid-state form eplerenone is brought down below about 400 μ m
90Particle diameter can improve the eplerenone of not preparation and comprise the bioavailability of the pharmaceutical composition of this solid-state form eplerenone.Therefore, do not prepare eplerenone or in preparation of pharmaceutical compositions, be used as the D of the eplerenone of raw material
90Particle diameter generally be lower than about 400 μ m, preferably be lower than about 200 μ m, more preferably less than about 150 μ m, also more preferably less than about 100 μ m, further more preferably less than about 90 μ m.
In one embodiment, D
90Particle diameter is not less than about 25 μ m.It is found that, for most of intended purposes, between the D of the about 400 μ m of about 25-
90Particle diameter generally has acceptable bioavailability, and avoided aspect the environmental pollution control relevant when grinding to form than small-particle expense and to the demand of its increase.When the major portion of eplerenone is eplerenone crystalline form H, in this particle size range, can especially obtain acceptable bioavailability, this is that part has due to the higher dissolution rate owing to this crystalline form at least.According to the present embodiment, suitable D
90Particle size range is the about 100 μ m of about 40-.Another suitable scope is the about 50 μ m of about 30-.Also having another suitable scope is the about 150 μ m of about 50-.Another suitable scope is the about 125 μ m of about 75-.
Can use any grinding, mill, micronization or the particle diameter method that reduces known in the art be processed into above-mentioned required particle size range arbitrarily with solid-state eplerenone.For example, air spray or crushing grinding are realized this purpose effectively.
When under the precursor of not too considering cost, needing the highest possible bioavailability, have been found that the particle diameter of solid-state form eplerenone is reduced to D
90Particle diameter is lower than the bioavailability that about 15 μ m can further strengthen not the eplerenone of preparation and comprise the pharmaceutical composition of this solid-state form eplerenone, though with above-mentioned D
90It also is like this that particle size range is compared.Therefore, in one embodiment, D
90Particle diameter is about 0.01 μ m (10nm)-Yue 15 μ m.In this embodiment, D
90Particle diameter preferably be lower than about 10 μ m, more preferably less than about 1 μ m, also more preferably less than about 800nm, still more preferably less than about 600nm, most preferably be lower than about 400nm.Use suitable D according to this
90Particle size range is the about 800nm of about 100-.Another suitable scope is the about 600nm of about 200nm-.Another suitable scope is the about 800nm of about 400nm-.Another suitable scope is the about 1 μ m of about 500nm-.
D
90The eplerenone that particle diameter is lower than the solid-state form of about 15 μ m can reduce technology according to suitable particle diameter known in the art and make.Such technology includes but not limited to the technology described in following patent and publication, each described patent and publication are all introduced the present invention with for referencial use:
Violanto ﹠amp; The US patent 4826689 of Fischer;
People's such as Liversidge US patent 5145684;
Na ﹠amp; The US patent 5298262 of Rajagopalan;
People's such as Liversidge US patent 5302401;
Na ﹠amp; The US patent 5336507 of Rajagopalan;
Illig ﹠amp; The US patent 5340564 of Sarpotdar;
Na ﹠amp; The US patent 5346702 of Rajagopalan;
People's such as Hollister US patent 5352459;
The US patent 5354560 of Lovrecich;
People's such as Courteille US patent 5384124;
The US patent 5429824 of June;
People's such as Ruddy US patent 5503723;
People's such as Bosch US patent 5510118;
People's such as Bruno US patent 5518187;
People's such as Eickhoff US patent 5518738;
People's such as De Castro US patent 5534270;
People's such as Canal US patent 5536508;
People's such as Liversidge US patent 5552160;
People's such as Eickhoff US patent 5560931;
People's such as Bagchi US patent 5560932;
People's such as Wong US patent 5565188;
People's such as Wong US patent 5569448;
People's such as Eickhoff US patent 5571536;
Desieno ﹠amp; The US patent 5573783 of Stetsko;
People's such as Ruddy US patent 5580579;
People's such as Ruddy US patent 5585108;
The US patent 5587143 of Wong;
People's such as Franson US patent 5591456;
The US patent 5622938 of Wong;
People's such as Bagchi US patent 5662883;
People's such as Bagchi US patent 5665331;
People's such as Ruddy US patent 5718919;
People's such as Wiedmann US patent 5747001;
International monopoly publication WO 93/25190;
International monopoly publication WO 96/24336;
International monopoly publication WO 98/35666.
In an exemplary method, be that coarse solid-state eplerenone is added to wherein in the undissolved basically therein liquid medium of eplerenone to form pre-mixing suspension.The concentration of eplerenone in this liquid medium can be about 60% for about 0.1%-, be preferably about 30% weight of about 5%-.The apparent viscosity of this pre-mixing suspension is preferably and is lower than about 1000cP.
This premixture directly can be carried out mechanical workout, for example use ball mill processing, with D with eplerenone
90Particle diameter is reduced to required scope.Perhaps, can be at first this premixture be stirred, for example stirs with roller press or Cowles type mixing tank, until observe formed wherein homodisperse liquid without any macroscopic big agglomerated thing till, grind then, for example grind with recirculation media mill machine.
Can be at surface-modifying agent abrasive grains in the presence of polymkeric substance or the wetting agent for example.Perhaps, after grinding, particle can be contacted with surface-modifying agent.It is coalescent that surface-modifying agent can reduce particulate, and have other advantage.
Should under the temperature of the eplerenone of significantly not degrading, reduce particle grain size.The processing temperature that is lower than about 30-40 ℃ generally is preferred.If necessary, available conventional refrigerating unit cools off processing unit (plant).For the purpose of convenient, this method is carried out under the room temperature and the tonnage that can grind safely and effectively.For example, the environment tonnage is the typical pressure that ball mill, attritor mill and vibration mill adopt.Controlled temperature can by with the grinding chamber chuck or be immersed in the frozen water and realize.Can adopt the about 3.5kg/cm of about 0.07-
2Tonnage, the general about 1.4kg/cm of about 0.7-that adopts
2Pressure.
After grinding is finished, for example filter, sieve etc. via screen cloth grinding medium is separated with drying or liquid dispersion form and grinding product with conventional isolation technique.
Pharmaceutical composition
Also comprise in the present invention be a class pharmaceutical composition, wherein comprise (i) eplerenone crystalline form H, choose wantonly and comprise the eplerenone that one or more are selected from other solid-state form of crystalline form L, solvation crystalline form and amorphous eplerenone together, (ii) one or more pharmaceutically acceptable carrier and/or thinner and/or auxiliary material (being referred to as " vehicle " in this article) and randomly (iii) comprise one or more active ingredients except that eplerenone.In preferred embodiments, all eplerenone that are included in the composition all are mutually pure form H basically; Yet if there is the combination of solid-state form, the weight ratio of preferred solid-state form as mentioned above.
Perhaps, all eplerenone that are included in the composition all are mutually pure solvation eplerenone crystal or amorphous eplerenone basically.
In another embodiment of the present invention, composition comprises form H and crystalline form L.In composition, the weight ratio of crystalline form L and form H is generally about 1: about 20: 1 of 20-.In another embodiment, this weight ratio is about 10: about 1: 5 of about 1: 10 of 1-, about 5: 1-, about 2: about 1: 2 of 1-; For example, this weight ratio is about 1: 1.
Can make the route of administration of the present composition and any appropriate adapt, that these route of administration include but not limited to is oral, cheek, hypogloeeis, parenteral route for example in the blood vessel, intraperitoneal, subcutaneous or intramuscular, part and rectum (for example by the suppository administration) approach.The eplerenone that these compositions comprise aequum is suitable for the pharmaceutically acceptable vehicle of required route of administration with one or more.
1. oral compositions and vehicle thereof
The oral dosage form of composition preferably comprises one or more vehicle that is selected from thinner, disintegrating agent, tackiness agent and tackiness agent, wetting agent, lubricant and antisticking agent.More preferably, for the ease of administration, such oral dosage form is made compacting in flakes or incapsulate.Gained tablet or capsule can contain immediate release formulations and/or controlled release preparation, and wherein controlled release preparation can for example provide in the dispersion of eplerenone in Vltra tears (HPMC).
By suitable selection and combination vehicle, can be provided at effectiveness, bioavailability, clean-up time, stability, eplerenone and vehicle compatibleness, security, dissolution characteristics, disintegration properties and/or other pharmacokinetics, chemistry and/or physical properties aspect etc. and show the composition that improves performance.Vehicle is preferably water-soluble or the water-dispersible material, and has wetting property to remedy the low water solubility of eplerenone.When composition was mixed with tablet, selected excipient composition provided the dissolving that shows improvement and the tablet of disintegration properties, hardness, shatter strength and/or fragility etc.
1.1 thinner
The present composition is optional to comprise one or more pharmaceutically acceptable diluents as vehicle.For example suitable vehicle comprises separately or unites the lactose of use, comprises lactose hydrous or Spherolac 100; Starch comprises the starch that can directly compress and hydrolyzed starch (Celutab for example
TMAnd Emdex
TM); N.F,USP MANNITOL; Sorbyl alcohol; Xylitol; Glucose (Cerelose for example
TM2000) and Glucose monohydrate; Dicalcium phosphate dihydrate; Thinner based on sucrose; The sugar that candy manufacturers produces; The calcium bisulfate monohydrate; Calcium sulfate dihydrate; Calcium lactate trihydrate particle; Dextran (dextrates); Inositol; The cereal solid of hydrolysis; Amylose starch; Mierocrystalline cellulose comprises the α of Microcrystalline Cellulose, food grade and amorphous cellulose (Rexcel for example
TM) and the Mierocrystalline cellulose of powdered; Lime carbonate; Glycine; Wilkinite; Polyvinylpyrrolidone etc.If present, such thinner accounts for about 99%, preferred about 85%, the 20%-about 80% more preferably from about of about 10%-of about 5%-of composition total weight altogether.Selected thinner (one or more) preferably shows suitable flowability and compressibility (when needs prepare tablet).
Separately or the lactose and the Microcrystalline Cellulose of uniting use be preferable absorbent.These two kinds of thinners are chemically all compatible with eplerenone.Use particle outer fiber element (being the Microcrystalline Cellulose that is added to behind the drying step in the wet granulation composition) to can be used for improving hardness (for tablet) and/or disintegration time.Lactose, especially Spherolac 100 are particularly preferred.Lactose generally provides the composition with mobile and/or dry property before suitable eplerenone release rate, stability, the compression with lower thinner cost.It provides the high-density matter that helps densification during granulate (wherein adopting wet granulation), and has therefore improved mixed flow.
1.2 disintegrating agent
The present composition is optional to comprise one or more pharmaceutically acceptable disintegrating agents as vehicle, particularly all the more so for tablet.Suitable disintegrants comprises separately or unites the starch of use, comprises the sodium starch glycolate (Explotab of Pen West for example
TM) and pre-gelled W-Gum (National for example
TM1551, National
TM1550 and Colocorn
TM1500), clay (Veegum for example
TMHV), Mierocrystalline cellulose Mierocrystalline cellulose, Microcrystalline Cellulose, methylcellulose gum, carboxymethyl cellulose and Xylo-Mucine, the croscarmellose sodium of the purifying (Ac-Di-Sol of FMC for example for example
TM), alginate, polyvinylpolypyrrolidone, natural gum is gum arabic, guar gum, tracasol, karaya, pectin and tragakanta for example.
During the preparation composition, disintegrating agent can add in the step of any appropriate, particularly adds during the lubricated step before granulation or before compressing tablet.If present, such disintegrating agent accounts for about 30%, preferred about 10%, the 0.2%-about 5% more preferably from about of about 0.2%-of about 0.2%-of composition total weight altogether.
For tablet or capsule disintegration, croscarmellose sodium is preferred disintegrating agent, and if present, and it preferably accounts for about 10%, about 7%, the 0.2%-about 5% more preferably from about also of 0.2%-more preferably from about of about 0.2%-of composition total weight.Croscarmellose sodium has brought disintegration ability in the good particle to the composition that the present invention granulates.
1.3. tackiness agent
The present composition is optional to comprise one or more pharmaceutically acceptable tackiness agents or tackiness agent as vehicle, particularly all the more so for tablet.Such tackiness agent and tackiness agent provide enough viscosity preferably for the powder of desiring compressing tablet, for example finalize the design (sizing), lubricate, compress and pack so that can carry out normal process operation, but make that tablet still can disintegration and make composition can be absorbed when taking in.Suitable binder and tackiness agent comprise separately or unite the gum arabic of use; Tragakanta; Sucrose; Gelatin; Glucose; Starch is such as but not limited to starch,pregelatinized (National for example
TM1551 and National
TM1550); Mierocrystalline cellulose is such as but not limited to methylcellulose gum and Xylo-Mucine (Tylose for example
TM); Alginic acid and alginate; Neusilin; Polyoxyethylene glycol (PEG); Guar gum; Polysaccharide acid; Wilkinite; Polyvinylpyrrolidone (polyvidone or PVP), for example 30 POVIDONE K 30 BP/USP-15, K-30 and K-29/32; The polyisobutene acid esters; HPMC; Hydroxypropylcellulose (Klucel for example
TM); And ethyl cellulose (Ethocel for example
TM).If present, about 25%, preferred about 15%, the 1%-about 10% more preferably from about of about 0.75%-of such tackiness agent and/or tackiness agent about 0.5%-of accounting for composition total weight altogether.
HPMC is used for providing fusible preferred adhesive to the powdered mixture of eplerenone preparation.If present, HPMC accounts for about 10%, preferred about 8%, the 2%-about 4% more preferably from about of about 1%-of about 0.5%-of composition total weight altogether.Generally can use the low molecular weight HPMC of viscosity, and the viscosity of the about 6cP of about 2cP-is preferred, the viscosity of the about 4cP of particularly about 2cP-for the about 8cP of about 2-.Described HPMC viscosity as 2% aqueous solution 20 ℃ of mensuration.It is about 35% that the methoxy content of HPMC is generally about 15%-, and that hydroxypropyl content generally is up to is about 15%, preferred about 2%-about 12%.
1.4. wetting agent
Eplerenone solution very not soluble in water.Therefore, the present composition is optional still preferably comprises one or more pharmaceutically acceptable wetting agents as vehicle.The such wetting agent of preferred selection can improve the condition of composition bioavailability to keep eplerenone and water closely to associate-it is believed that.
The limiting examples that can be used as the tensio-active agent of wetting agent in the present composition comprises quaternary ammonium compound, for example benzalkonium chloride, benzethonium chloride and cetyl pyridinium hydrochloride, dioctyl sodium sulfosuccinate, polyoxyethylene alkyl phenyl ether is nonoxinol 9, nonoxinol 10 and octoxinol 9 for example, poloxamer (polyoxyethylene and polyoxypropylene block copolymers), polyoxyethylene fatty acid glyceryl ester and oil be polyoxyethylene (8) caprylic/capric monoglyceride and the triglyceride (Labrasol of Gattefoss é for example for example
TM), polyoxyethylene (35) Viscotrol C and polyoxyethylene (40) hydrogenated castor oil; Polyxyethylated ester is polyoxyethylene (20) cetearyl ether for example, and polyoxyethylene fatty acid ester is polyoxyethylene (40) stearate for example, and Sorbitan ethoxylate is polysorbas20 and the tween 80 (Tween of ICI for example for example
TM80), the propylene glycol fatty acid ester propylene glycol laurate (Lauroglycol of Gattefoss6 for example for example
TM), sodium lauryl sulphate, lipid acid and salt thereof is oleic acid, sodium oleate and trolamine oleate for example, glycerol fatty acid ester is monostearin for example, Isosorbide Dinitrate is anhydro sorbitol one lauric acid ester, anhydro sorbitol monooleate, anhydro sorbitol monopalmitate and anhydro sorbitol monostearate for example, tyloxapol and their mixture.If present, such wetting agent accounts for about 15%, preferred about 10%, the 0.5%-about 5% more preferably from about of about 0.4%-of about 0.25%-of composition total weight altogether.
Wetting agent as anion surfactant is preferred.Sodium lauryl sulphate is particularly preferred wetting agent.If present, sodium lauryl sulphate accounts for about 7%, about 4%, the 0.5%-about 2% more preferably from about also of 0.4%-more preferably from about of about 0.25%-of composition total weight.
1.5. lubricant, glidant and antisticking agent
The present composition is optional to comprise one or more pharmaceutically acceptable lubricants and/or glidant as vehicle.Examples of suitable lubricants and/or glidant comprise separately or unite the glycerine behapate (Compritol for example of use
TM888); Stearic acid and salt thereof comprise Magnesium Stearate, calcium stearate and sodium stearate; Hydrogenated vegetable oil (Sterotex for example
TM); Colloidal silica; Talcum powder; Wax; Boric acid; Sodium Benzoate; Sodium acetate; Sodium fumarate; Sodium-chlor; The DL-leucine; Polyoxyethylene glycol (Carbowax for example
TM4000 and Carbowax
TM4000); Sodium oleate; Sodium lauryl sulphate; And Stepanol MG.If present, about 10%, preferred about 8%, the 0.25%-about 5% more preferably from about of about 0.2%-of such lubricant and/or glidant about 0.1%-of accounting for composition total weight altogether.
Magnesium Stearate is preferred lubricant, and it is used for for example in the friction that reduces during the compressing tablet between device and the granulation mixture.
Suitable antisticking agent comprises talcum powder, W-Gum, DL-leucine, sodium lauryl sulphate and Metallic stearates.Talcum powder is preferred antisticking agent or glidant, and it is used for for example reducing the adhesion of preparation and apparatus surface and the static (static) in the reduction mixture.If present, talcum powder accounts for about 10%, about 5%, the 0.5%-about 2% more preferably from about also of 0.25%-more preferably from about of about 0.1%-of composition total weight.
1.6 other vehicle
Other vehicle for example tinting material, correctives and sweeting agent is that pharmaceutical field is known, and can be used in the present composition.Can be with tablet coating, for example with enteric coating with tablet coating, perhaps dressing not.The present composition can also comprise for example buffer reagent.
1.7 preferred oral compositions
In one embodiment, the present composition comprises eplerenone and one or more cellulose family vehicle of aequum.Term " cellulose family vehicle " is meant the vehicle that comprises the Mierocrystalline cellulose or derivatives thereof, includes but not limited to Mierocrystalline cellulose, Microcrystalline Cellulose and the alkylcellulose of purifying and their derivative and salt (for example methylcellulose gum, ethyl cellulose, hydroxypropylcellulose, HPMC, carboxymethyl cellulose, comprise the Xylo-Mucine of croscarmellose sodium etc.).Preferably, at least a such cellulose family vehicle is selected from (C
1-6Alkyl) Mierocrystalline cellulose and their derivative and salt.More preferably, described cellulose family vehicle is selected from hydroxyl (C
2-4Alkyl)-(C
1-4Alkyl) Mierocrystalline cellulose and their derivative and salt.
The composition of this embodiment preferably also comprises the vehicle that one or more are selected from thinner, disintegrating agent, tackiness agent, wetting agent, lubricant and antisticking agent.These compositions more preferably comprise one or more and are selected from lactose, Microcrystalline Cellulose, croscarmellose sodium, HPMC, sodium lauryl sulphate, Magnesium Stearate and talcous vehicle.These compositions also more preferably comprise Spherolac 100, Microcrystalline Cellulose, croscarmellose sodium and HPMC, most preferably also comprise one or more and are selected from sodium lauryl sulphate, Magnesium Stearate and talcous other vehicle.
In this embodiment, if necessary, listed single vehicle can be chosen wantonly with other suitable vehicle and replace.Acceptable alternative vehicle and eplerenone are all chemical compatible with other vehicle.Though can use other thinner, disintegrating agent, tackiness agent and tackiness agent, wetting agent, lubricant and/or antisticking agent or glidant, comprise eplerenone nano particle, lactose, Microcrystalline Cellulose, Xylo-Mucine and HPMC and optional sodium lauryl sulphate, Magnesium Stearate and/or the talcous composition that comprises is better than other composition in pharmacokinetics, chemistry and/or physical features combined aspects usually.
In another embodiment, the present composition comprises:
About 95% eplerenone of about 1%-;
About 99% pharmaceutically acceptable diluent of about 5%-;
About 0.5%-about 30% pharmaceutically acceptable disintegrating agent; With
About 0.5%-about 25% pharmaceutically acceptable tackiness agent;
Wherein said per-cent all is by weight.Such composition can be chosen wantonly and also comprise about 0.25%-about 15% pharmaceutically acceptable wetting agent; About 0.1%-about 10% pharmaceutically acceptable lubricant; And/or about 0.1%-about 15% pharmaceutically acceptable antisticking agent.
In another embodiment, the present composition is and contains eplerenone and the form of the oral unit dosage form of cellulose family vehicle, preferred tablet or capsule as defined above.Said composition preferably comprises one or more and is selected from Spherolac 100, Microcrystalline Cellulose, croscarmellose sodium, Vltra tears, sodium lauryl sulphate, Magnesium Stearate and talcous vehicle.
2. parenteral administration composition
But the solid-state eplerenone form of the present invention parenteral administration, for example by the solid-state eplerenone of intravenously, intramuscular or subcutaneous injection liquid vehicle for example the suspension in salt solution, glucose solution or the water come administration.Suspension composition can comprise the suitable vehicle component of the vehicle that is selected from oral compositions disclosed above.
3. percutaneous administration composition
Other composition can be the form of part or percutaneous administration paste or creme, described paste or creme comprise the solid-state eplerenone that is scattered in wherein, wherein the content of eplerenone, preferably about 0.2%-about 20% weight, more preferably from about 0.4%-about 15% weight about 30% for for example about 0.075%-.For the purpose of favourable, such part or percutaneous administration composition can comprise can promote the compound of eplerenone via skin absorption or transdermal.This skin penetration promotes that examples for compounds comprises methyl-sulphoxide and related compound.
The new solid-state form of eplerenone can also use drug storehouse storage and porous membranous type or solid substrate type patch to come transdermal administration.For any situation, eplerenone all via film from drug storehouse storage or microcapsule, be delivered to continuously with individual's skin or the contiguous eplerenone permeable adhesive of mucous membrane in.If eplerenone is via skin absorption, the eplerenone of controlled and predetermined amount of flow can be administered to the recipient.For microcapsule, but the also effect of skinning of encapsulation agent.
Treatment or prevention method
The present invention also comprises the aldosterone-mediated illness or the method for disease for the treatment of and/or preventing, described method comprises the individuality of suffering from or easily suffer from described illness or disease with the solid-state eplerenone of treatment significant quantity or the medicine composite for curing that comprises solid-state eplerenone, it is eplerenone crystalline form H that but wherein said solid-state eplerenone has a test section at least, and remaining part comprises the eplerenone crystal and the amorphous eplerenone of one or more eplerenone crystalline forms L, solvation.Such method can be used for treating and/or preventing illness or the disease that needs to use aldosterone antagonists in the individuality, include but not limited to treat aldosteronism venereal disease disease, for example hypertension, heart failure comprise that cardiac insufficiency, liver cirrhosis, collagen are excessive, fibrosis, benign prostatauxe and dysthymia disorders.
Except can be used for treating the people, the eplerenone of these solid-state forms and pharmaceutical composition thereof also can be used for for example veterinary treatment of horse, dog and cat of pet, external and farm-animals.
The eplerenone of solid-state form and composition thereof can (i) partially or completely replace other aldosterone receptor antagonist in combination therapy, and/or (ii) carry out combination therapy with other medicines.Term " combination therapy " is meant uses every kind of medicine in a sequential manner in the scheme that the drug regimen beneficial effect is provided, with with simultaneously mode drug administration together basically, for example in the single capsule or single injection of these promoting agents, perhaps in a plurality of independent formulations that have a kind of promoting agent respectively or injection, use with fixed proportion.The limiting examples of such combination therapy comprises as using aldosterone receptor antagonist and angiotensin II receptor antagonists to treat cardiovascular disorder in uniting described in the international monopoly publication WO 96/24373, as using aldosterone receptor antagonist and Angiotensin II antagonist to treat congestive heart failure in uniting described in the international monopoly publication WO 96/40257, as uniting the use aldosterone receptor antagonist described in the international monopoly publication WO 96/24372, ACE inhibitor and diuretic(s) are treated heart failure, and all these publications are all introduced the present invention with for referencial use.
Embodiment
Following embodiment describes the method for preparation various solid-state form eplerenone as herein described in detail.These are described in detail within the scope of the present invention, and are to illustrate of the present invention, rather than limit the scope of the invention by any way.Unless otherwise noted, otherwise all per-cents all be by weight.The eplerenone raw material that uses in each following embodiment all is according to scheme 1 preparation of the international monopoly publication WO 98/25948 that above quotes.
Embodiment 1: by high purity eplerenone feedstock production butanone compound with by this solvate preparation
Eplerenone crystalline form L
A. prepare the butanone compound
Under the magnetic of 900rpm stirs, 437mg high purity eplerenone (purity＞99%, and diepoxide and 11, the total content of 12-epoxide＜0.2%) is dissolved in the 10ml butanone by on hot plate, being heated to boil.Under the magnetic that continues stirs, gained solution is cooled to room temperature.In case reach room temperature, just this solution is transferred in 1 ℃ of bath, and continued to stir 1 hour.From this cold soln, collect butanone compound solid by vacuum filtration.
B. prepare eplerenone crystalline form L
With the butanone compound solid that makes as mentioned above in baking oven under 100 ℃, normal pressure dry 4 hours.Confirmed that by DSC and XRPD analysis this exsiccant solid is pure crystalline form L.
Embodiment 2: prepare other solvate by high-purity raw
According to identical with embodiment 1 basically method, replace butanone to prepare other solvate with following solvents respectively: n-propyl alcohol, 2 pentanone, acetate, acetone, butylacetate, chloroform, ethanol, isopropylcarbinol, isobutyl acetate, Virahol, methyl acetate, ethyl propionate, propyl carbinol, n-Octanol, propyl acetate, propylene glycol, the trimethyl carbinol, tetrahydrofuran (THF) and toluene.
Embodiment 3: by vapor diffusion growing and preparing butanone compound
By warm on hot plate 400mg eplerenone (purity＞99.9%) is dissolved in the 20ml butanone, to form stock solution.With butanone this stock solution of 8ml is diluted to 10ml, gained solution is called 80% diluted sample.With butanone this stock solution of 4ml is diluted to 10ml (40% diluted sample).With butanone this stock solution of 2ml is diluted to 10ml (20% diluted sample).Will each diluted sample in the 20ml scintillation vial transfer to and contain in the dry cylinder of a small amount of hexane as anti-solvent (anti-solvent).Should seal by the drying cylinder, and make hexane vapor be diffused in the butanone solution.In 24 hours, in 80% diluted sample, grown the crystal of eplerenone butanone compound.
Embodiment 4: prepare the eplerenone solvate crystals by Rotary Evaporators
About 400mg eplerenone of weighing (purity＞99.9%) places the 250ml round-bottomed flask.The solvent that 150ml is selected from butanone and embodiment 2 listed solvents is added in this flask, if necessary the solution mild heat is dissolved until eplerenone.The gained settled solution is placed Buchi Rotary Evaporators with about 85 ℃ of bath temperature.When stopping except that desolvating during the about 10ml solvent of residue in the flask.Analyze the gained solid to determine crystalline form by proper method (for example XPRD, DSC, TGA, microscopy etc.).
Embodiment 5: slurries transform
About 150mg eplerenone crystalline form L and 150mg eplerenone crystalline form H are added in the 5ml ethyl acetate.The gained slurries are spent the night with the stirring of 300rpm magnetic.Second day by filtering collection gained solid sample.By the XRPD analyzing samples, the result shows that this sample is made up of eplerenone crystalline form L fully.
Embodiment 6:(a) by low-purity eplerenone feedstock production solvate with (b) by the gained solvent
Compound prepares eplerenone crystalline form H
By being added to prepare in the 7ml scintillation vial with a certain amount of eplerenone that is enough to provide this quality of 100mg gross sample together, the impurity of aequum contains the aforesaid diepoxide of different amounts or 11, the sample of 12-epoxide impurity.The content of impurity is shown in table 6A and 6B in each sample, and wherein impurity is respectively diepoxide or 11, the 12-epoxide.In each scintillation vial, add miniature magnetic stirrer and 1ml butanone.With the capping of scintillation vial pine loose ground, solid is dissolved by on hot plate, being heated to backflow under stirring at magnetic.When dissolving is finished, continuing under the stirring gained solution to be cooled to room temperature.Collect the gained solid by vacuum filtration then, and analyze by XRPD immediately.Then solid is placed 100 ℃ of baking ovens, and under normal pressure dry 1 hour.Analyze the exsiccant solid by XRPD, determine form H content at the area of the form H diffraction peak of about 12.1 ° of 2 θ by monitoring.All XRPD diffractograms all write down on the InelMultipurpose diffractometer.
The composition of eplerenone raw material among table 6A: the embodiment 6
| The % diepoxide | Eplerenone (mg) | Diepoxide (mg) |
| 0 | 100.44 | 0 |
| 1 | 99.08 | 1.24 |
| 2 | 98.09 | 2.24 |
| 3 | 97.08 | 3.04 |
| 5 | 95.09 | 5.04 |
The composition of eplerenone raw material among table 6B: the embodiment 6
| %11, the 12-epoxide | Eplerenone (mg) | 11,12-epoxide (mg) |
| 0 | 101.38 | 0 |
| 1 | 99.23 | 1.10 |
| 5 | 94.97 | 5.36 |
| 10 | 90.13 | 10.86 |
A. diepoxide result
Accompanying drawing 78 has shown to derive from and has mixed (a) 0%, (b) 1%, (c) 3% and (d) the XRPD figure of the wet cake of butanone crystalline butanone compound of 5% diepoxide.For the ease of relatively, peak intensity has been carried out stdn (normalized).In diffractogram without any the characteristic peak of form H or diepoxide.This figure is the feature of eplerenone butanone compound.
Accompanying drawing 79 has shown to derive from and has mixed (a) 0%, (b) 1%, (c) 3% and (d) 5% diepoxide butanone crystallizing and drying solid XRPD figure.For the ease of relatively, peak intensity has been carried out stdn.Be not detect any form H in 0% or 1% the corresponding dry sample of butanone crystallization with the doped level of diepoxide wherein.Be to have detected form H in 3% or 5% the corresponding dry sample of butanone crystallization with the doped level of diepoxide wherein.For each sample, at the area of the form H diffraction peak of about 121 ° of 2 θ and the form H content estimated shown in table 6C.
Butanone crystallization gained data among table 6C: the embodiment 6
| % diepoxide in the raw material | % diepoxide (HPLC) in the crystal | Form H peak area at 12.1 ° of 2 θ | The form H % content of |
| 0 | 0 | Do not detect | 0 |
| 1 | 0.29 | Do not detect | 0 |
| 3 | 0.58 | 1168 | 10 |
| 5 | 1.05 | 4157 | 30 |
The result who reports among the table 6C has confirmed to exist during desolvation diepoxide to influence the formation of eplerenone crystalline form H.In the time of on diepoxide being incorporated into and/or being adsorbed onto butanone compound crystal, induced the formation of form H.
Carry out second 3% diepoxide mix experiment with the analyte preparation approach to desolvation during the influence of formed form H amount.In this experiment, will be by the butanone compound separated into two parts of doping crystallization acquisition.First part does not handle, and second section grinds lightly with pestle in mortar, to induce the len coloboma of higher level.With these two portions all under normal pressure in 100 ℃ of dryings 1 hour.Analyze the exsiccant solid by XRPD.Accompanying drawing 80 has shown that wherein (a) do not grind this solvate before the drying, is to have ground this solvate before the drying (b) from the XRPD figure of the drying solid of the butanone crystallization acquisition of mixing 3% diepoxide.XRPD figure shows, compares with the sample that does not grind, and contains more form H in the sample of grinding.These results show that the condition of separation and processing butanone compound can influence the formed crystalline form of desolvation.
B.11,12 epoxide results
Accompanying drawing 81 shown derive from mixed (a) 0%, (b) 1%, (c) 5% and (d) 10% 11, the XRPD figure of the wet cake of 12-epoxide butanone crystallization butanone compound.For the ease of relatively, peak intensity has been carried out stdn.In diffractogram without any the characteristic peak of form H or 11.12-epoxide.This figure is the feature of eplerenone butanone compound.
Accompanying drawing 82 has shown to derive from and has mixed (a) 0%, (b) 1%, (c) 5% and (d) 10%11,12-epoxide butanone crystallizing and drying solid XRPD figure.For the ease of relatively, peak intensity has been carried out stdn.With wherein 11, the doped level of 12-epoxide is not detect any form H in 0%, 1% or 5% the corresponding dry sample of butanone crystallization.With wherein 11, the doped level of 12-epoxide is to have detected form H in 10% the corresponding dry sample of butanone crystallization.For each sample, at the area of the form H diffraction peak of about 12.1 ° of 2 θ and the form H content estimated shown in table 6D.
Butanone crystallization gained data among table 6D: the embodiment 6
| %11 in the raw material, the 12-epoxide | Form H peak area at about 12.1 ° of 2 θ | The form H % content of |
| 0 | Do not detect | 0 |
| 1 | Do not detect | 0 |
| 5 | Do not detect | 0 |
| 10 | 1541 | 10-15 |
The result who reports among the table 6D has confirmed to have 11 during desolvation, and the 12-epoxide influences the formation of eplerenone crystalline form H.For the impurity level of inducing in the required butanone crystallization of formation eplerenone crystalline form H, 11, as if the 12-epoxide be greater than diepoxide.
Embodiment 7. crystallizations and dry influence to final crystalline form
Carry out following 4 experiments with minute precipitation and crystallization and dry influence: (i) the butanone crystallization (2 of eplerenone to final crystalline form
3+ 3 experimental statisticses designs), the (ii) crystallization of inferior quality mother liquor resistates, (iii) add the form H crystal seed the high purity eplerenone crystallization and (iv) add the crystallization of the low-purity eplerenone of crystalline form L crystal seed.Variable in these experiments comprises speed of cooling, material purity level and crystalline terminal temperature.In this embodiment, the high purity eplerenone is defined as the eplerenone that ultrapure (HPLC) ground, and it is 89% eplerenone that the low-purity eplerenone is defined as purity.In order to prepare the low-purity eplerenone, the mother liquor stripping that will in the process of preparation eplerenone, be obtained, and mix to obtain to contain 61.1% eplerenone, 12.8% diepoxide and 7.6%11, the material of 12-epoxide.Then this material being mixed to obtain purity with capacity high purity eplerenone is 89% eplerenone.
A. butanone crystallization
In this butanone crystallization experiment, all batches all carry out with 60g high purity eplerenone.High terminal point is defined as 45 ℃, and low terminal point is defined as 5 ℃.High speed of cooling is defined as 3 ℃/minute, and low speed of cooling is defined as 0.1 ℃/minute.Mid point is that 1.5 ℃ of/minute speed of cooling, purity are eplerenone and 25 ℃ of terminal points of 94.5%.
After carrying out background reading with FTIR, the 250ml butanone is placed 1 liter of Mettler RC-1, in the MP10 reactor, and stir with 100rpm.After the scanning several times, in this reactor, add eplerenone, and then add the 470ml butanone.Stirring velocity is increased to 500rpm with suspended solids, and this mixture temperature is increased to 80 ℃.The temperature of this mixture is remained on 80 ℃ to guarantee the eplerenone dissolving.In the gained clear solution, generally can see black or white dot.With required speed this mixture temperature is reduced to required terminal point by the slope cooling then, kept 1 hour, be poured into then and move in the liquid bottle and filtration, obtained wet cake in this terminal temperature.Wash this reactor, move liquid bottle and wet cake with the 120ml butanone then.For every increment this, will the wet cake of about 10g vacuum-drying under 75 ℃, slight nitrogen blended standard conditions in vacuum drying oven.Under high and low condition, pass through fluid-bed drying dry wet cake.For fluidised bed drying, high conditional definition is 100 ℃, 4 blower fans is installed that low condition is defined as 40 ℃, 1 blower fan is installed.
B. crystallization inferior quality mother liquor resistates
In the experiment of crystallization inferior quality mother liquor resistates, the eplerenone and the 720ml butanone of 60g 61.1% purity directly are added to 1 liter of Mettler RC-1, in the MP10 reactor. before in being added to reactor, impure eplerenone is not mixed with the high purity eplerenone.With gained mixture heating up to 80 ℃, it is opaque slurries in room temperature.Continue crystallization, filtering this mixture in 45 ℃ under the cooling conditions rapidly.
C. add the form H crystal seed
In the experiment that adds the form H crystal seed, 60g high purity eplerenone and 720ml butanone are added to 1 liter of Mettler RC-1, in the MP10 reactor.With this mixture heating up to 80 ℃, be cooled to 25 ℃ with 1.5 ℃/minute speed then.When solution is cooled to 62 ℃, to wherein adding the mutually pure form H crystal of 3g with induced crystallization.Described form H crystal seed is to make by the cooking process in following embodiment 9.
D. add crystalline form L crystal seed
In the experiment that adds crystalline form L crystal seed, the eplerenone of 66.6g 89.3% (making by 48.3g high purity eplerenone is mixed with 18.3g 61.1% eplerenone) and 720ml butanone are added to 1 liter of Mettler RC-1, in the MP10 reactor.With this mixture heating up to 80 ℃, be cooled to 25 ℃ with 1.5 ℃/minute speed then.When solution is cooled to 63 ℃, to wherein adding the mutually pure crystalline form L crystal of 3g with induced crystallization.Described crystalline form L crystal seed is by making in crystallization described in the embodiment 1 and desolvation method.
E. result
These experiment gained are the result be reported among the table 7A.
In the butanone crystallization experiment, have only when using the low-purity eplerenone that contains diepoxide, just to detect form H.The level of also observing diepoxide in the end product under higher speed of cooling increases.
The experiment of crystallization inferior quality mother liquor resistates has generated downhill, detect to find its mixture of diepoxide and eplerenone crystalline form H seemingly by XRPD.
In the product that the experiment that adds the form H crystal seed (use the high purity eplerenone, add the form H crystal seed) generates, analyze it according to XRPD and contain 77% form H, but it all is a form H according to DSC.Yet for the linearity that surpasses about 15% form H, the XRPD model was never tested.In the middle of these 4 experiments, this experiment is a unique experiment that does not exist diepoxide promptly to generate form H.
It all is the product of crystalline form L that the experiment of adding crystalline form L crystal seed (use the low-purity eplerenone, add crystalline form L crystal seed) has generated.
As if for the high condition fluidised bed drying of eplerenone, the gained data are consistent with the dry gained data of vacuum drying oven.The result who is obtained from the low condition fluidised bed drying is different with the dry gained result of vacuum drying oven.
The result of table 7A: embodiment 7
| Speed of cooling (℃/min.) | The cooling terminal point (℃) | Raw material % purity | Nucleation temperature (℃) | %11, the 12-epoxide 1 | The % diepoxide 1 | The desolvation crystalline is analyzed | The % productive rate | % form H (XRPD) |
| 3 | 45 | 94.5 | 57.0 | ND | ND | 100.3 | 66.1 | |
| 3 | 5 | 94.5 | 54.9 | ND | ND | 100.3 | 98.1 | ND |
| 0.1 | 45 | 94.5 | 60.9 | ND | ND | 100.3 | ND | |
| 0.1 | 5 | 94.5 | 63.4 | ND | ND | 100.5 | 79.3 | |
| 3 | 45 | 61.1 | 4.8 | 36.6 | 43.3 | 27 | 100 2 | |
| 3 | 45 | 89.3 | 52.2 | 0.49 | 0.88 | 98.3 | 62 | 29 |
| 3 | 5 | 89.3 | 53.3 | 0.56 | 1.0 | 98.1 | 87 | 9 |
| 1.5 | 25 | 100 | 59.0 | 0.18 | 0.36 | 99.4 | 75 | 5 |
| 0.1 | 45 | 89.3 | 63.3 | 0.20 | 0.44 | 99.4 | 36 | 31 |
| 0.1 | 5 | 89.3 | 61.4 | 0.18 | 0.40 | 99.5 | 87 | ND |
| 1.5 | 25 | 100 | 60.6 | 0.18 | 0.36 | 99.5 | 79.2 | ND |
| 1.5 | 25 | 100 | 55.9 | 0.38 | 0.80 | 98.6 | 80.5 | ＜3％ |
| 1.5 | 25 | 100 add the form H crystal seed | 0.03 | ND | 100.4 | 82.2 | 77/100 3 | |
| 1.5 | 25 | 89.3 add crystalline form L crystal seed | 0.33 | 0.50 | 97.5 | 80.2 | ND |
1With solvate in vacuum drying oven in 75 ℃ of dried weight %
2Analyze by XRPD and to find the mixture of form H and diepoxide seemingly
3Analyze seemingly 77% form H and by dsc analysis 100% form H seemingly by XRPD
ND=does not detect
F. material purity
Accompanying drawing 83 has shown based on showing the data that 7A reported, the isometric chart of product purity, material purity, speed of cooling and terminal temperature.This isometric chart shows, uses the higher degree eplerenone can generate the higher degree product when the beginning crystallization.As if the crystalline terminal temperature little to the influence of product purity.Yet it is influential that speed of cooling seems, caused generating the low slightly product of purity than the piece speed of cooling.In fact, under the speed of cooling than piece, the level of diepoxide is generally higher.
Accompanying drawing 84 expression be, in order to determine the purity of end product is had the variable (if any) of remarkable statistics influence, with half standard map of this isometric chart result drafting.Material purity has maximum remarkable statistics influence to product purity, and the interaction between the influence of speed of cooling and speed of cooling and the material purity also has significance,statistical.
Accompanying drawing 85 is based on these results' interaction diagram, its expression be the influence of the interaction partners product purity between material purity and the speed of cooling.When using the high purity eplerenone, speed of cooling looks very little or without any influence to the influence of final purity.Yet, when using low-purity eplerenone (89.3% eplerenone raw material), along with the increase product purity of speed of cooling has descended.This result shows, when when higher speed of cooling is carried out crystallization, can crystallization go out more impurity.
G. form H content
The data that 7A reported, the isometric chart of form H weight fraction, material purity, speed of cooling and terminal temperature are shown in being based on of accompanying drawing 86 expressions.This isometric chart shows, uses the eplerenone of higher degree can obtain more a spot of form H when the beginning crystallization.As if the crystalline terminal temperature also influential to the form of end product.Speed of cooling looks little to the formation of form H influence, though in the presence of impurity, in low terminal temperature with can some form Hs of generation than the cooling of piece speed.
Accompanying drawing 87 expression be, in order to determine variable (if any), with half standard map of this isometric chart result drafting with remarkable statistics influence to the content of form H in the end product.Look that the interaction between material purity, crystalline terminal temperature and this two variablees has remarkable statistics influence.
Accompanying drawing 88 be based on the table data that 7A reported interaction diagram, its expression be the influence of the interaction partners end product purity between material purity and the terminal temperature.When using the high purity eplerenone, look that terminal temperature is very little to the form H content influence.In two experiments using pure eplerenone, all do not generate any form H.Yet, when using low-purity eplerenone (the eplerenone raw material of 89.3% purity), in two experiments, all generated form H, and generated more form H significantly in higher terminal temperature.
Table 7B has reported and has used fluidized-bed (Lab-Line/P.R.L.Hi-Speed fluidized bed dryer, Lab-Line Instruments, Inc) or the weight fraction of the form H of measuring in vacuum drying oven (BaxterScientific Products vacuum drying oven, Model DP-32) the exsiccant material.For the comparable material of exsiccant in high fluidized-bed or vacuum drying oven, observed similar form H content.Yet for the comparable material of exsiccant in low fluidized-bed, the result who is observed is different with vacuum drying oven.
Table 7B: operational variable is to the influence of form H content
| Speed of cooling | Terminal point | Impurity level | Drying conditions | The % form H |
| High | High | High | Vacuum drying oven | 29 |
| High | High | High | High fluidized- | 25 |
| High | High | High | Low fluidized-bed | 4.7 |
| Low | Low | Low | Vacuum drying oven | ND |
| Low | Low | Low | High fluidized-bed | ND |
| Low | Low | Low | Low fluidized-bed | 5.5 |
ND=does not detect
Embodiment 8: adopt desolvation crystalline form L from butanone
10g eplerenone crystalline form H and 80ml butanone are merged.With this mixture heating up to refluxing (79 ℃), and under this temperature stir about 30 minutes.Then by with these slurries 65 ℃, 50 ℃, 35 ℃ and 25 ℃ keep respectively 90 minutes with the gained slurries with progressively, stop (holdpoint) point mode cool off.Filter this slurries, and wash with about 20ml butanone.The isolated solid of institute is at first dry on filter, then in vacuum drying oven in 40-50 ℃ of drying.In vacuum drying oven, finish drying in 90-100 ℃.Yield with 82% has obtained desolvated solid.XRPD, MIR and DSC have confirmed that this solid has crystalline form L crystalline structure.
Embodiment 9: prepare form H with solvent boiling low-purity eplerenone raw material
A. use the alcohol solvent boiling
24.6g low-purity eplerenone (purity that HPLC measures is 64%) is merged with 126ml ethanol 3A.These slurries are heated to backflow, and remove distillate.When the 126ml solvent is removed by air distillation, add simultaneously after 126ml ethanol 3A. solvent turnover finishes, this mixture is cooled to 25 ℃ and stirred 1 hour.With the gained solid filtering, and with ethanol 3A washing, air-dry then, obtained the ethanol compound.With this solvate in vacuum drying oven in 90-100 ℃ further dry 6 hours, obtained 14.9g eplerenone crystalline form H.
B. use the butanone solvent boiling
In another boiling method,, then this mixture is cooled to room temperature with 1g low-purity eplerenone (purity of mensuration is 65%) boiling 24 hours in the 4ml butanone.In case cooling is promptly collected the gained solid by vacuum filtration, confirmed that by the XRPD analysis it is the butanone compound.With this solid at 100 ℃ of dry 30-60 minutes.XPRD confirms that this exsiccant solid is pure form H.
Embodiment 10: prepare crystalline form L with solvent boiling high purity eplerenone raw material
A. use the alcohol solvent boiling
With about 24 hours of 1g high purity eplerenone boiling in 8ml ethanol.Then this solution is cooled to room temperature, and collects solid by vacuum filtration.Analyze this solid by XRPD immediately after the filtration, the result shows that this solid is solvate (supposition is the ethanol compound).Then with this solid 100 ℃ under normal pressure dry 30 minutes.Analyze this exsiccant solid by XRPD, the result has confirmed that it mainly is crystalline form L (not detecting any form H).
B. use the butanone solvent boiling
With about 2 hours of 1g high purity eplerenone boiling in the 4ml butanone.Then this solution is cooled to room temperature, and collects solid by vacuum filtration.Analyze this solid by XRPD immediately, the result shows that this solid is solvate (supposition is the butanone compound).Then with this solid 100 ℃ under normal pressure dry 30-60 minute.Analyze this exsiccant solid by XRPD, the result has confirmed that it mainly is crystalline form L, does not exist any form H diffraction peak.
Embodiment 11: direct crystallization crystalline form L from solution
Method A
By being heated to 75 ℃ the 2.5g eplerenone is dissolved in the ethyl acetate.This solution is kept 30 minutes to guarantee dissolving fully at 75 ℃, be cooled to 13 ℃ with 1 ℃/minute speed of cooling then.The gained slurries were stirred 2 hours with 750rpm with the overhead type agitator.Collect solid by vacuum filtration, and in vacuum drying oven in 40 ℃ of dryings 1 hour.This solid XRPD figure and DSC differential thermogram are the features of eplerenone crystalline form L.This solid TGA shows, do not have weight loss being up to 200 ℃ of these solids.
Method B
In other method, the 2g eplerenone is dissolved in the mixture of 350ml 15% acetonitrile and 85% water by on hot plate, heating under stirring at magnetic.In case eplerenone is dissolved, under magnetic stirs with this solution in the room temperature cool overnight.Collect the gained solid by vacuum filtration.Crystal has birefringence effect, and has trilateral sheet crystalline habit.This solid has XRPD and the dsc analysis feature of eplerenone crystalline form L.TGA shows and is being up to 200 ℃ also without any weight loss.
Method C
In other method, the 640mg eplerenone is placed 50ml flask with 20ml ethylbenzene.The gained slurries are heated to 116 ℃, and this mixture has become settled solution, with 30 minutes it is cooled to 25 ℃ then.During cooling 84 ℃ of beginning nucleation.The gained solid is filtered out from this solution, air-dry, obtained 530mg solid (yield 83%).Hot-stage microscopy and XRPD have confirmed that this solid is eplerenone crystalline form L.
Method D
In other method, be added to the 1.55g eplerenone in the 2.0ml oil of mirbane and be heated to 200 ℃.The gained slurries are spent the night 200 ℃ of stirrings, and this mixture has become settled solution, by the natural air convection current it is cooled to room temperature to isolate solid then.Confirmed that by XRPD and polarization microscope this solid is eplerenone crystalline form L.
Method E
In other method, 5.0g eplerenone (purity＞99%) is added in 82g (104ml) methyl alcohol.Under stirring, this solution is heated to 60 ℃, and under this temperature, keeps dissolving fully guaranteeing in 20 minutes with 210rpm.Under agitation this solution is cooled to-5 ℃ then with 0.16 ℃/minute speed.By filter collecting the gained solid, and in vacuum drying oven in 40 ℃ of vacuum-dryings 20 hours.DSC and XRPD analyze and have confirmed that this exsiccant solid is pure eplerenone crystalline form L.
Method F
In other method, 6.0g eplerenone (contain 9% alcoholic acid ethanol compound, its corrected purity is 95.2%) is added in 82g (104ml) methyl alcohol.Under stirring, this solution is heated to 60 ℃, and under this temperature, keeps dissolving fully guaranteeing in 20 minutes with 210rpm.With 0.14 ℃/minute speed this solution is cooled to 50 ℃ then, and under this temperature, kept 2.5 hours.Under agitation this solution is cooled to-5 ℃ then with 0.13 ℃/minute speed.By filter collecting crystal, and in vacuum drying oven, analyze and confirmed that this exsiccant solid is pure eplerenone crystalline form L. in 16 hours .DSC of 40 ℃ of vacuum-dryings and XRPD
Embodiment 12: direct crystallization form H from solution
150.5mg diepoxide and 2.85g eplerenone are added in the 1.5ml oil of mirbane.This mixture was stirred several hours at 200 ℃ of magnetic.By the natural air convection current gained slurries are cooled to room temperature then.With the sample drying and by polarization microscope and XRPD analyzing samples.This sample of XRPD analysis revealed is the mixture of form H and crystalline form L.This crystal is translucent at microscopically, and this shows desolvation and (changing into form H or crystalline form L) are not taken place.
Embodiment 13: by pulverizing the amorphous eplerenone of preparation
With about 60g eplerenone (purity＞99.9%) on about 1 half steel system Wig-L-Bug vessel filling.Steel ball and lid are placed on this sample container, and stirred 30 seconds by this Wig-L-Bug device.The surface of eplerenone from this Wig-L-Bug container scraped off, and with this container restir 30 seconds.By XRPD and dsc analysis gained solid, found that this solid is the mixture of amorphous eplerenone and eplerenone crystalline form L.
Embodiment 14: prepare amorphous eplerenone by lyophilize
About 100mg eplerenone crude product of weighing places the beaker that contains 400ml water.With gained mixture mild heat 5 minutes, ultrasonic then, and restir 5 minutes is to obtain dispersion liquid.About 350ml eplerenone dispersion liquid is filled in the 1000ml round-bottomed flask that contains 50ml HPLC water.With this dispersion liquid in dry ice/acetone batch rapid freezing 1-2 minute.Flask is connected on Labconco Freezone 4.5 lyophilizers, and general's content dried overnight wherein.With the solid transfer in the flask in brown vial.Under polarization microscope in 10 *, 1.25 * optivar magnification observes the little aliquots containig in cargille oil (1.404), and observe and have 95% amorphous eplerenone at least.Accompanying drawing 89 and 90 has shown the XRPD figure and the DSC differential thermogram of amorphous eplerenone.In accompanying drawing 89, be because due to the aluminium sample container at 39 ° of 2 observed peak of θ.
Embodiment 15: the solubleness of eplerenone crystalline form L
At pH 7 (100mM phosphate buffered saline buffer) in 5,25 and 40 ℃ of water solubilities that detect eplerenone.At 5 and 25 ℃ about 30mg eplerenone crystalline form L is mixed to form the eplerenone slurries with about 10ml damping fluid.At 40 ℃ about 40mg eplerenone crystalline form II is mixed to form the eplerenone slurries with about 10ml damping fluid.For each condition, with duplicate preparation sample.Slurries are carried out balance in the water electromagnetic shaker is bathed, and measure the content of eplerenone in the solution with the 1st, 5,12,19,27 and 36 day the timed interval by ultraviolet-visible spectrophotometry (245nm) under proper temperature.To carry out fair average determining the eplerenone solubleness under each temperature in the data under each temperature, and be reported in the table 8.When balance finished in the 36th day, analyze the residual solid of each time point by DSC and TGA, found that it is eplerenone crystalline form L.
Table 8: the solubleness of eplerenone crystalline form L
| Temperature (℃) | Crystalline form L solubleness (mg/ml) |
| 5 | 0.24 |
| 25 | 0.29 |
| 40 | 0.39 |
Embodiment 16: measure intrinsic dissolution rate
Measure the intrinsic dissolution rate of following 4 kinds of eplerenone polymorphic form samples: (i) make water as anti-solvent, according to embodiment 11, the method that method B is identical is by the eplerenone crystalline form L that directly crystallization makes from acetonitrile; (ii) according to the identical mode of embodiment 9 method A, the eplerenone crystalline form H that makes by boiling in ethanol; The (iii) mixture of 5% form H and 95% crystalline form L; (iv) carry out micronization with particle that the eplerenone crystalline form L:10% weight with following size distribution is provided below 9 μ m, the particle of 50% weight below the 22 μ m and the particle of 90% weight below 41 μ m.
The 150mg eplerenone of weighing also places the intrinsic lysing chamber of VanKel.Use the Carver tabletting machine in the 8280kPa compacting in flakes with powder.Then sample is fixed on the intrinsic dissolver.Used dissolve medium is the solution of 1% sodium lauryl sulphate (SDS) in HPLC water.All tests all are to carry out 2 hours 37 ℃ of tests.Before beginning experiment, with the 500ml dissolve medium in the dissolving bathroom in 37 ℃ of balances 30 minutes.From each dissolution vessel, take out initial sample, with at initial time (T
0) test.Then the eplerenone tablet is reduced in the dissolve medium.Extract sample at the fixed time at interval to measure dissolution rate.Careful operation is to prevent forming bubble in tablet surface.By UV absorption measurement method at the 243nm analyzing samples.(proofreaied and correct volume and according to concentration-time curve with the surface area normalized (0.5cm of solution tablet
2)) the slope of straight line portion calculate intrinsic dissolution rate.
Accompanying drawing 91 has been reported the intrinsic dissolution rate of these 4 kinds of samples of being measured.These experiments show that the intrinsic dissolution rate of eplerenone crystalline form H is faster than eplerenone crystalline form L.Relatively compression is measured with the XRPD that does not compress eplerenone and has been confirmed that polymorphic form does not transform mutually under contractive condition or during dissolution experiment.
Embodiment 17: eplerenone polymorphic form composition
Preparation has the tablet of forming shown in the table 9 that contains 25mg, 50mg, 100mg and 200mg dosage eplerenone crystalline form L.
The composition of table 9: embodiment 17 tablets
| Component | % weight |
| Eplerenone crystalline form L | 29.41 |
| Eplerenone crystalline form H | Do not detect |
| | 42.00 |
| Microcrystalline Cellulose, NF (Avicel TM?PH-101) | 18.09 |
| Croscarmellose sodium, NF (Ac-Di-Sol TM) | 5.00 |
| HPMC，USP(#2910，Pharmacoat TM603) | 3.00 |
| Sodium lauryl sulphate, NF | 1.00 |
| Talcum powder, USP | 1.00 |
| Magnesium Stearate, NF | 0.5 |
| Altogether | 100.00 |
Embodiment 18: eplerenone polymorphic form composition
Preparation contain 100mg dosage eplerenone and have shown in the table 10 capsule formed (hard gelatin capsule, #0)
The capsular composition of the 100mg of table 10: embodiment 18
| Component | Content (mg) |
| Eplerenone crystalline form L | 90.0 |
| Eplerenone crystalline form H | 10.0 |
| Lactose hydrous, NF | 231.4 |
| Microcrystalline Cellulose, NF | 45.4 |
| Talcum powder, USP | 10.0 |
| Croscarmellose sodium, NF | 8.0 |
| Sodium lauryl sulphate, NF | 2.0 |
| Colloidal silica, NF | 2.0 |
| Magnesium Stearate, NF | 1.2 |
| The total filling weight of capsule | 400.0 |
Embodiment 19: eplerenone polymorphic form composition
Preparation contains 200mg dosage eplerenone and has the capsule of forming shown in the table 11 (hard gelatin capsule, big or small #0).
The capsular composition of the 200mg of table 11: embodiment 19
| Composition | Content (mg) |
| Eplerenone crystalline form L | 190.0 |
| Eplerenone crystalline form H | 10.0 |
| Lactose hydrous, NF | 147.8 |
| Microcrystalline Cellulose, NF | 29.0 |
| Talcum powder, USP | 10.0 |
| Croscarmellose sodium, NF | 8.0 |
| Sodium lauryl sulphate, NF | 2.0 |
| Colloidal silica, NF | 2.0 |
| Magnesium Stearate, NF | 1.2 |
| The total filling weight of capsule | 400.0 |
Embodiment 20: the preparation of eplerenone fine powder
At first, exsiccant eplerenone butanone compound is sieved so that it deblocks via 20 eye mesh screens on the Fitz runner milling.Then, under cooled with liquid nitrogen, use Alpine Hosakawa post bolt disk pin type to grind (stud disk pin mill) crushing operation with about 250kg/ hour feed rate the solid that deblocks is carried out the pin type grinding.The D of the eplerenone after pin type is ground
90Particle diameter is about 65-100 μ m.
Embodiment 21: the eplerenone particle diameter is to the influence of pharmacokinetic parameter in the dog experiment
In dog model, studied of the influence of the particle diameter of eplerenone crystalline form L to eplerenone plasma concentration and relative bioavailability.One of female Sexual health screech owl short-leg beagle (beagle dogs) intragastric administration of four body weight 8-12kg is contained the quick-release capsules (#0, White-opalescent) of following table 12 described prescriptions, about then 10ml water.
The capsular composition of table 12: embodiment 21 used eplerenone
| Composition | Weight percent | Content (mg) |
| Eplerenone crystalline form L | 50.00 | 200.00 |
| Lactose hydrous (Fast-Flo) | 36.95 | 147.80 |
| Microcrystalline Cellulose (Avicel TM?PH-102) | 7.25 | 29.00 |
| Sodium lauryl sulphate | 0.50 | 2.00 |
| Croscarmellose sodium | 2.00 | 8.00 |
| Talcum powder | 2.50 | 10.00 |
| Colloidal silica | 0.50 | 2.00 |
| Magnesium Stearate | 0.30 | 1.20 |
| Total amount | 100.00 | 400.00 |
Before giving Drug Capsule, allow dog fasting 15-20 hour, allow the dog feed at least after 4 hours again in administration then.Collect blood sample (about 3 milliliters) by venipuncture in administration respectively after 0,0.5,1,2,3,4,6,8 and 24 hour and place the freeze pipe that contains heparin.Immediately blood sample is placed on ice.After centrifugal about 15 minutes, finish separated plasma from blood sample.The plasma sample that obtains is freezing and store until analysis under-20 ℃ of temperature approximately.Using the LC/MS/MS method analyzes.
Use three kinds of preparations of this four dog tests, every kind of preparation has shown in the table 12 to be formed, but has different eplerenone particle diameters.The D of eplerenone raw material
90Particle diameter is respectively about 212 μ m, about 86 μ m and about 36 μ m.Be that 5 days minimum is cleaned the phase pitch time of twice successive administration.Its average result is shown in following table 13 and 14.Calculate relative bioavailability from AUC result, select D
90The preparation that is 86 μ m is as standard.
Table 13: serum eplerenone concentration (μ g/ml), embodiment 21
| Time (hour) | D 90?212μm | ?D 90?86μm | ?D
90? |
| 0 | 0 | 0 | 0 |
| 0.5 | 1.83 | 3.65 | 1.99 |
| 1 | 2.40 | 6.18 | 5.86 |
| 2 | 3.77 | 6.89 | 6.77 |
| 3 | 2.85 | 5.70 | 6.60 |
| 4 | 2.61 | 4.39 | 5.56 |
| 6 | 1.63 | 3.11 | 3.31 |
| 8 | 1.10 | 1.90 | 2.09 |
| 24 | 0.0252 | 0.032 | 0.0706 |
Table 14: pharmacokinetics (PK) parameter that from embodiment 21 data, calculates
| The PK parameter | D 90?212μm | ?D 90?86μm | ?D 90?36μm |
| ?C max(μg/ml) | 3.98 | 7.02 | 7.39 |
| ?T max(hour) | 1.50 | 1.75 | 2.25 |
| ?AUC((μg/ml)hr) | 26.6 | 49.2 | 53.1 |
| Relative bioavailability (%) | 53.25 | 100 | 107.9 |
Embodiment 22: the eplerenone particle diameter is to the influence of pharmacokinetic parameters in human experimentation
In human model, studied of the influence of the particle diameter of eplerenone crystalline form L to eplerenone plasma concentration and relative bioavailability.Three kinds of used pharmaceutical compositions are as shown in table 15 below.Allowed the eplerenone crystalline form L composition of the medicament forms that the experimenter takes single 100 milligrams of dosage at the 1st, 8,15,22 and 29 day according to random fashion.Take medicine at every turn and all took 180 ml waters at 0800 hour.-0.5 (before the administration) after administration, 0.5,1,2,3,4,6,8,10,12,16,24,36 and 48 hour blood sample collection are used for the eplerenone pharmacokinetic analysis.
Use effective HPLC method, adopt MS/MS to detect the plasma concentration of determining eplerenone.Its pharmacokinetic data available is shown in table 16.Use laser light scattering and be determined at the size distribution of the eplerenone crystalline form L that uses in the preparation of compositions in dry powder.
Table 15: embodiment 22 used eplerenone compositions (weight %)
| Component | Capsules A | Tablet A | Capsule B |
| Eplerenone crystalline form L (D 90?40μm) (D 90?82μm) (D 90?96μm) | 25 -- -- | -- 30 -- | -- -- 25 |
| | -- | 42 | 57.86 |
| Lactose hydrous | 57.8 | -- | -- |
| Microcrystalline Cellulose (Avicel TM?PH-101) (Avicel TM?PH-102) | 11.4 -- | 17.5 1 -- | -- 11.34 |
| Croscarmellose sodium (Ac-Di-Sol TM) | 2 | 5 | 2 |
| HPMC(Pharmacoat TM603) | -- | 3 | -- |
| Sodium lauryl sulphate | 0.5 | 1 | 0.5 |
| Talcum powder | 2.5 | 1 | 2.5 |
| Magnesium Stearate | 0.3 | 0.5 | 0.3 |
| Colloidal silica | 0.5 | -- | 0.5 |
| | 100 | 100 | 100 |
1In 7.5% particle, outside 10% particle
Table 16: pharmacokinetics (PK) parameter that goes out from embodiment 22 data computation
| The PK parameter | 100mg capsules A (D 90?40μm) | 100mg tablet A (D 90?82μm) | 100mg capsule B (D 90?96μm) |
| C max(ng/ml) | 1747 | 1704 | 1669 |
| T max(hour) | 1.8 | 1.8 | 1.3 |
| AUC((ng/ml)hr) | 11349 | 11945 | 11981 |
Although the present invention is described by specific embodiments, the details of these schemes can not be interpreted as limitation of the present invention.
Claims (68)
1. eplerenone medicine that comprises 90%-100% form H crystal eplerenone, this form H crystal eplerenone has rhombic system and its X-ray powder diffraction pattern has the peak at 12.0 ± 0.2 ° of 2 θ.
2. the eplerenone medicine of claim 1 also comprises crystalline form L crystal eplerenone, and this crystalline form L crystal eplerenone has oblique system.
3. claim 1 or 2 eplerenone medicine also comprise the solvation crystalline form of eplerenone.
4. the eplerenone medicine of claim 3, wherein said solvation crystalline form is selected from butanone compound, 2 pentanone compound, acetate compound, acetone compound, butylacetate compound, chloroform compound, ethanol compound, isopropylcarbinol compound, isobutyl acetate compound, methyl acetate compound, ethyl propionate compound, propyl carbinol compound, n-Octanol compound, n-propyl alcohol compound, Virahol compound, propyl acetate compound, propylene glycol compound, trimethyl carbinol compound, tetrahydrofuran (THF) compound, toluene compound and tert.-butyl acetate compound.
5. the eplerenone medicine of claim 4, wherein, the solvation crystalline form is a butanone compound crystalline form.
6. the eplerenone medicine of claim 1, wherein existing eplerenone is at least 95% mutually pure form H crystal eplerenone.
7. claim 1,2,3,4 or 6 eplerenone medicine, its form is a particle, this particulate D
90Particle size is less than 400 μ m.
8. the eplerenone medicine of claim 7, its form is a particle, this particulate D
90Particle size is less than 200 μ m.
9. the eplerenone medicine of claim 7, its form is a particle, this particulate D
90Particle size is less than 150 μ m.
10. the eplerenone medicine of claim 7, its form is a particle, this particulate D
90Particle size is less than 100 μ m.
11. claim 1,2,3,4 or 6 eplerenone medicine, its form is a particle, this particulate D
90Particle size is 25-400 μ m.
12. the eplerenone medicine of claim 11, its form are particle, this particulate D
90Particle size is 40-100 μ m.
13. the eplerenone medicine of claim 11, its form are particle, this particulate D
90Particle size is 30-50 μ m.
14. claim 1,2,3,4 or 6 eplerenone medicine, its form is a particle, this particulate D
90Particle size is 50-150 μ m.
15. the eplerenone medicine of claim 14, its form are particle, this particulate D
90Particle size is 75-125 μ m.
16. claim 1,2,3,4 or 6 eplerenone medicine, its form is a particle, this particulate D
90Particle size is less than 15 μ m.
17. the eplerenone medicine of claim 16, its form are particle, this particulate D
90Particle size is less than 10 μ m.
18. the eplerenone medicine of claim 16, its form are particle, this particulate D
90Particle size is less than 1 μ m.
19. claim 1,2,3,4 or 6 eplerenone medicine, described medicine contains the crystal growth promoters of one or more form Hs.
20. claim 1,2,3,4 or 6 eplerenone medicine, described medicine contains on one or more crystallography basically the compound with eplerenone crystalline form H isomorphism, wherein, described compound is the eplerenone solvate that is selected from following solvent: acetate, acetone, methyl acetate, propyl acetate, butylacetate, isobutyl acetate, tert.-butyl acetate, chloroform, ethanol, n-propyl alcohol, Virahol, propyl carbinol, ethyl propionate, propylene glycol, tetrahydrofuran (THF) and toluene.
21. claim 1,2,3,4 or 6 eplerenone medicine, described medicine contain one or more and are selected from (a) 4 α, 5 α; 9 α, 11 α-diepoxy-17-hydroxyl-3-oxo-17 alpha-pregnane-7 α, 21-dioctyl phthalate hydrogen 7-methyl esters, gamma lactone; (b) 11 α, 12 alpha-epoxy-17s-hydroxyl-3-oxo-17 α-pregnant-4-alkene-7 α, 21-dioctyl phthalate hydrogen 7-methyl esters, gamma lactone; (c) 17-hydroxyl-3-oxo-17 α-pregnant-4,9 (11)-diene-7 α, 21-dioctyl phthalate hydrogen 7-methyl esters, the compound of gamma lactone.
22. the eplerenone medicine of claim 21, wherein, the described compound altogether and the weight ratio of described medicine are 1: 100.
23. the eplerenone medicine of claim 22, wherein, described weight ratio is 3: 100.
24. the eplerenone medicine of claim 22, wherein, described weight ratio is 3: 100-1: 5.
25. contain claim 1,2,3,4 or 6 the eplerenone medicine and the medicinal compositions of one or more pharmaceutically acceptable vehicle, the amount of wherein said eplerenone is 10-1000mg.
26. the composition of claim 25, wherein the amount of eplerenone is 25,50,100 or 200mg.
27. the composition of claim 25, wherein said eplerenone medicine is to have D
90Particle size exists less than the particle form of 400 μ m.
28. the composition of claim 27, wherein the eplerenone medicine is a particle form, this particulate D
90Particle size is less than 200 μ m.
29. the composition of claim 27, wherein the eplerenone medicine is a particle form, this particulate D
90Particle size is less than 150 μ m.
30. the composition of claim 27, wherein the eplerenone medicine is a particle form, this particulate D
90Particle size is less than 100 μ m.
31. the composition of claim 25, wherein said eplerenone medicine is to have D
90The particle form of particle size 25-400 μ m exists.
32. the composition of claim 31, wherein the eplerenone medicine is a particle form, this particulate D
90Particle size is 10-100 μ m.
33. the composition of claim 31, wherein the eplerenone medicine is a particle form, this particulate D
90Particle size is 30-50 μ m.
34. the composition of claim 25, wherein said eplerenone medicine is to have D
90The particle form of particle size 50-150 μ m exists.
35. the composition of claim 34, wherein the eplerenone medicine is a particle form, this particulate D
90Particle size is 75-125 μ m.
36. the composition of claim 25, wherein said eplerenone medicine is to have D
90Particle size exists less than the particle form of 15 μ m.
37. the composition of claim 36, wherein the eplerenone medicine is a particle form, this particulate D
90Particle size is less than 10 μ m.
38. the composition of claim 36, wherein the eplerenone medicine is a particle form, this particulate D
90Particle size is less than 1 μ m.
39. the pharmaceutical composition of claim 25 preparation be used for the treatment of or the medicine of the illness of prophylaxis of aldosterone-mediated or disease in purposes.
40. the purposes of claim 39, wherein said illness or disease are selected from, and hypertension, heart failure, liver cirrhosis, collagen are excessive, fibrosis, benign prostatauxe and dysthymia disorders.
41. the purposes of claim 39, wherein said illness or disease are hypertension.
42. the purposes of claim 39, wherein said illness or disease are in heart failure.
43. prepare the method for form H crystal eplerenone, this method is included in high boiling solvent or contains the solution that the eplerenone starting raw material is provided in the solvent mixture of high boiling solvent; With the direct crystalline form of crystallization eplerenone from described solution, this crystalline form has rhombic system and its X-ray powder diffraction pattern has the peak at 12.0 ± 0.2 ° of 2 θ, and wherein said crystallisation step is to carry out under the temperature of the change transition temperature that is higher than described crystalline form.
44. the method for claim 43, wherein before the crystallisation step or during in solvent or solvent mixture, add the crystal seed of the described form H crystalline form of eplerenone.
45. the method for claim 43 also is included in the D that crystallizes into less than 400 μ m
90Grind the step of eplerenone after the particle size.
46. prepare the method for form H crystal eplerenone, this method comprises that (a) is at the solvent that can form eplerenone solvation crystalline form or contain the eplerenone starting raw material of the molten low-purity that disappears in the mixture of this kind solvent; (b) from this solvent or mixture the crystallization eplerenone to form the step of solvate; (c) this solvate desolvation had rhombic system and its X-ray powder diffraction pattern have the peak at 12.0 ± 0.2 ° of 2 θ eplerenone crystalline form to provide.
47. the method for claim 46, wherein said solvent are selected from butanone, 1-propyl alcohol, 2 pentanone, acetate, acetone, butylacetate, chloroform, ethanol, isopropylcarbinol, isobutyl acetate, methyl acetate, ethyl propionate, propyl carbinol, n-Octanol, Virahol, propyl acetate, propylene glycol, the trimethyl carbinol, tetrahydrofuran (THF), toluene, methyl alcohol and tert.-butyl acetate.
48. the method for claim 46, wherein said solvent is selected from butanone and ethanol.
49. the method for claim 46, also being included in desolvates changes into D less than 400 μ m
90Grind the step of eplerenone before or after the particle size.
50. the method for claim 46, wherein form H crystal eplerenone has the phase purity of at least 90% form H.
51. prepare the method for form H crystal eplerenone, this method comprises that (a) is at the solvent that can form eplerenone solvation crystalline form or contain the molten eplerenone starting raw material that disappears in the mixture of this kind solvent; (b) from this solvent or mixture the crystallization eplerenone to form the step of solvate; (c) this solvate desolvation is had rhombic system and its X-ray powder diffraction pattern and at 12.0 ± 0.2 ° of 2 θ the eplerenone crystalline form at peak is arranged to provide, wherein before the crystallisation step or during in solvent or solvent mixture, add the crystal seed of the described crystalline form of eplerenone.
52. the method for claim 51, wherein form H crystal eplerenone has the phase purity of at least 90% form H.
53. by the prepared crystal eplerenone of each method of claim 43-52.
54. the solvation crystalline form of an eplerenone, it is selected from 1-propyl alcohol compound, 2 pentanone compound, acetate compound, acetone compound, butylacetate compound, chloroform compound, isopropylcarbinol compound, isobutyl acetate compound, methyl acetate compound, ethyl propionate compound, propyl carbinol compound, n-Octanol compound, propyl acetate compound, propylene glycol compound, trimethyl carbinol compound, tetrahydrofuran (THF) compound, toluene compound, methyl alcohol compound and tert.-butyl acetate compound.
55. prepare the method for solvation eplerenone crystalline form, this method comprises that (a) is being selected from following solvent: the step of the molten eplerenone starting raw material that disappears in the solvent of 1-propyl alcohol, 2 pentanone, acetate, acetone, butylacetate, chloroform, isopropylcarbinol, isobutyl acetate, methyl acetate, ethyl propionate, propyl carbinol, n-Octanol, propyl acetate, propylene glycol, the trimethyl carbinol, tetrahydrofuran (THF), toluene, methyl alcohol and tert.-butyl acetate; (b) from this solvent or mixture the crystallization eplerenone to form the step of solvate.
56. amorphous eplerenone.
57. the amorphous eplerenone of claim 56, it is mutually pure amorphous eplerenone.
58. comprise the eplerenone medicine of the amorphous eplerenone of claim 56, it also comprises and has rhombic system and its X-ray powder diffraction pattern have the peak at 12.0 ± 0.2 ° of 2 θ form H crystal eplerenone.
59. the eplerenone medicine of claim 58, wherein, the weight ratio of described amorphous eplerenone and described form H crystal eplerenone is 1: 99.
60. the eplerenone medicine of claim 58, wherein, the weight ratio of described amorphous eplerenone and described form H crystal eplerenone is at least 1: 9.
61. the medicine of claim 60, wherein, the weight ratio of amorphous eplerenone and form H crystal eplerenone is at least 1: 1.
62. comprise the eplerenone medicine of the amorphous eplerenone of claim 56, it also comprises and has monoclinic eplerenone crystalline form L crystal.
63. the eplerenone medicine of claim 62, the weight ratio of wherein said amorphous eplerenone and described crystalline form L crystal eplerenone is 1: 99-99: 1.
64. the eplerenone medicine of claim 62, the weight ratio of wherein said amorphous eplerenone and described crystalline form L crystal eplerenone is at least 1: 9.
65. the eplerenone medicine of claim 64, the weight ratio of wherein said amorphous eplerenone and described crystalline form L crystal eplerenone is at least 1: 1.
66. comprise the eplerenone medicine of the amorphous eplerenone of claim 56, the eplerenone crystalline form of the solvation that it also comprises.
67. the eplerenone medicine of claim 66, wherein, described solvation crystalline form is selected from butanone compound, 2 pentanone compound, acetate compound, acetone compound, butylacetate compound, chloroform compound, ethanol compound, isopropylcarbinol compound, isobutyl acetate compound, methyl acetate compound, ethyl propionate compound, propyl carbinol compound, n-Octanol compound, n-propyl alcohol compound, Virahol compound, propyl acetate compound, propylene glycol compound, trimethyl carbinol compound, tetrahydrofuran (THF) compound, toluene compound and tert.-butyl acetate compound.
68. prepare the method for amorphous eplerenone, this method comprises that (a) forms the step of eplerenone dispersion in water; (b) step of this dispersion of quick freezing; (c) lyophilize through the refrigerated dispersion to form the step of amorphous eplerenone.
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16980799P | 1999-12-08 | 1999-12-08 | |
| US16963999P | 1999-12-08 | 1999-12-08 | |
| US16968299P | 1999-12-08 | 1999-12-08 | |
| US16969099P | 1999-12-08 | 1999-12-08 | |
| US16960899P | 1999-12-08 | 1999-12-08 | |
| US16955699P | 1999-12-08 | 1999-12-08 | |
| US60/169682 | 1999-12-08 | ||
| US60/169690 | 1999-12-08 | ||
| US60/169639 | 1999-12-08 | ||
| US60/169807 | 1999-12-08 | ||
| US60/169556 | 1999-12-08 | ||
| US60/169608 | 1999-12-08 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100368081A Division CN1557833A (en) | 1999-12-08 | 2000-12-04 | Eplerenone crystalline form exhibiting enhanced dissolution rate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1377365A CN1377365A (en) | 2002-10-30 |
| CN1152886C true CN1152886C (en) | 2004-06-09 |
Family
ID=27558585
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB008057788A Expired - Fee Related CN1152886C (en) | 1999-12-08 | 2000-12-04 | Eplerenone crystalline form exhibiting enhanced dissolution rate |
| CNA2004100368081A Pending CN1557833A (en) | 1999-12-08 | 2000-12-04 | Eplerenone crystalline form exhibiting enhanced dissolution rate |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100368081A Pending CN1557833A (en) | 1999-12-08 | 2000-12-04 | Eplerenone crystalline form exhibiting enhanced dissolution rate |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1177204A2 (en) |
| JP (1) | JP2003516414A (en) |
| KR (1) | KR100607923B1 (en) |
| CN (2) | CN1152886C (en) |
| AU (1) | AU784946B2 (en) |
| BR (1) | BR0008057A (en) |
| CA (1) | CA2362669A1 (en) |
| CO (1) | CO5280211A1 (en) |
| EA (1) | EA007934B1 (en) |
| HK (1) | HK1050536A1 (en) |
| HU (1) | HUP0203032A3 (en) |
| IL (3) | IL144764A0 (en) |
| MX (1) | MXPA01008056A (en) |
| MY (1) | MY131878A (en) |
| NO (1) | NO20013856L (en) |
| NZ (2) | NZ513961A (en) |
| PE (1) | PE20010917A1 (en) |
| WO (1) | WO2001042272A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040072797A1 (en) * | 2002-03-20 | 2004-04-15 | Pornanong Aramwit | Storage stable eplerenone formulation |
| US7235655B2 (en) | 2002-03-22 | 2007-06-26 | Pharmacia & Upjohn Company | Processes to prepare eplerenone |
| CA2582496A1 (en) | 2007-03-20 | 2008-09-20 | Apotex Pharmachem Inc. | Improved process for the preparation and purification of eplerenone |
| EP2977084B1 (en) | 2010-05-10 | 2017-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| US9241944B2 (en) | 2010-06-16 | 2016-01-26 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods and compositions for stimulating reepithelialisation during wound healing |
| EP3362095B1 (en) | 2015-10-13 | 2020-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| EP3490606B8 (en) | 2016-07-26 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| CN108059648A (en) * | 2017-12-30 | 2018-05-22 | 合肥久诺医药科技有限公司 | A kind of eplerenone solvate and preparation method thereof |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
| WO2023204729A1 (en) * | 2022-04-19 | 2023-10-26 | Общество с ограниченной ответственностью "Гелеспон" | Pharmaceutical compositions based on a novel substance of 4-[2-(1н-imidazol-4-yl)-ethylcarbamoyl]-butanoic acid and method for producing said substance |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559332A (en) * | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
| KR100523409B1 (en) * | 1996-12-11 | 2005-10-24 | 지.디. 썰 엘엘씨 | Processes for preparation of 9,11-epoxy steroids and intermediates useful therein |
| AU778559B2 (en) * | 1999-03-05 | 2004-12-09 | G.D. Searle Llc | Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease |
-
2000
- 2000-12-04 BR BR0008057-8A patent/BR0008057A/en not_active IP Right Cessation
- 2000-12-04 KR KR1020017010043A patent/KR100607923B1/en not_active IP Right Cessation
- 2000-12-04 AU AU20492/01A patent/AU784946B2/en not_active Ceased
- 2000-12-04 NZ NZ513961A patent/NZ513961A/en not_active IP Right Cessation
- 2000-12-04 WO PCT/US2000/032416 patent/WO2001042272A2/en not_active Application Discontinuation
- 2000-12-04 CN CNB008057788A patent/CN1152886C/en not_active Expired - Fee Related
- 2000-12-04 CN CNA2004100368081A patent/CN1557833A/en active Pending
- 2000-12-04 EA EA200100871A patent/EA007934B1/en not_active IP Right Cessation
- 2000-12-04 EP EP00983781A patent/EP1177204A2/en not_active Withdrawn
- 2000-12-04 HU HU0203032A patent/HUP0203032A3/en unknown
- 2000-12-04 MX MXPA01008056A patent/MXPA01008056A/en not_active Application Discontinuation
- 2000-12-04 CA CA002362669A patent/CA2362669A1/en not_active Abandoned
- 2000-12-04 IL IL14476400A patent/IL144764A0/en active IP Right Grant
- 2000-12-04 NZ NZ530028A patent/NZ530028A/en not_active IP Right Cessation
- 2000-12-04 JP JP2001543569A patent/JP2003516414A/en not_active Withdrawn
- 2000-12-06 PE PE2000001300A patent/PE20010917A1/en not_active Application Discontinuation
- 2000-12-06 MY MYPI20005734A patent/MY131878A/en unknown
- 2000-12-11 CO CO00094075A patent/CO5280211A1/en not_active Application Discontinuation
-
2001
- 2001-08-06 IL IL144764A patent/IL144764A/en not_active IP Right Cessation
- 2001-08-08 NO NO20013856A patent/NO20013856L/en not_active Application Discontinuation
-
2003
- 2003-04-15 HK HK03102731A patent/HK1050536A1/en not_active IP Right Cessation
-
2006
- 2006-06-22 IL IL176511A patent/IL176511A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20013856D0 (en) | 2001-08-08 |
| WO2001042272A3 (en) | 2001-11-29 |
| EP1177204A2 (en) | 2002-02-06 |
| HK1050536A1 (en) | 2003-06-27 |
| EA007934B1 (en) | 2007-02-27 |
| EA200100871A1 (en) | 2002-04-25 |
| MXPA01008056A (en) | 2003-07-21 |
| AU784946B2 (en) | 2006-08-03 |
| HUP0203032A3 (en) | 2003-04-28 |
| JP2003516414A (en) | 2003-05-13 |
| PE20010917A1 (en) | 2001-09-10 |
| WO2001042272A9 (en) | 2002-12-12 |
| IL144764A (en) | 2007-08-19 |
| CN1377365A (en) | 2002-10-30 |
| WO2001042272A2 (en) | 2001-06-14 |
| CO5280211A1 (en) | 2003-05-30 |
| KR20010112261A (en) | 2001-12-20 |
| NO20013856L (en) | 2001-10-08 |
| KR100607923B1 (en) | 2006-08-04 |
| HUP0203032A2 (en) | 2002-12-28 |
| AU2049201A (en) | 2001-06-18 |
| CA2362669A1 (en) | 2001-06-14 |
| CN1557833A (en) | 2004-12-29 |
| MY131878A (en) | 2007-09-28 |
| BR0008057A (en) | 2002-04-23 |
| IL176511A (en) | 2007-08-19 |
| IL144764A0 (en) | 2002-06-30 |
| NZ530028A (en) | 2005-08-26 |
| NZ513961A (en) | 2004-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1275962C (en) | Novel anticholinergic agents that can be used as medicaments and method for the production thereof | |
| CN1152886C (en) | Eplerenone crystalline form exhibiting enhanced dissolution rate | |
| CN1291986C (en) | Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions | |
| CN1214008C (en) | Therapeutic biaryl derivatives | |
| CN1022184C (en) | Process for preparing (1 H-imidzol-1-ylmethyl) substituted benzotriazole derivatives | |
| CN1251671C (en) | Beta secretase inhibitors | |
| CN1192031C (en) | Epothilones derivatives, their synthesis and uses | |
| CN101035759A (en) | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | |
| CN1234738A (en) | Olanzapine dihydrate D | |
| CN101052631A (en) | Crystalline mycophenolate sodium | |
| CN1463191A (en) | Low hygroscopic aripiprazole drug substance and processes for prepn. thereof | |
| CN1675177A (en) | Modafinil polymorphic forms | |
| CN1890220A (en) | A crystalline of the salt form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same | |
| CN1076124A (en) | A kind of method that is used to prepare the enteric coating oral medicine that contains sour unstable compound | |
| CN1523979A (en) | Pharmaceutical compositions of adsorbates of amorphous drug | |
| CN1558905A (en) | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | |
| CN101066264A (en) | Solid olmesartan medoxmil dispersion and its prepn and medicinal application | |
| CN101068916A (en) | Use of atazanavir for improving the pharmacokinetics of drugs metabolized by UGT1A1 | |
| CN1926104A (en) | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | |
| CN1976930A (en) | 6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido(3,2-b)indol-2-ones useful as anti-infective pharmaceutical agents | |
| CN1080639A (en) | The inhibitor of 5-α-testosterone reductase | |
| CN1433427A (en) | Eplerenone crystalline form | |
| CN1162153C (en) | Benzothiophenes, formulations containing same, and methods | |
| CN1272842A (en) | 2-acylaminopropanamines as tachykinin receptor antagonists | |
| CN1165533C (en) | Spiropiperidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1050536 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040609 Termination date: 20111204 |